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Gastrointestinal microbiome studies have failed to include fungi in total
community analyses. As a result, their diversity and function in the gut is poorly
understood. Recent work has begun to uncover the role intestinal fungi play in diet,
immune system development, interactions with other microorganisms in the gut, and
pathogenesis of diseases. Advances in sequencing technologies allow for the ability to
profile the fungal gut microbiome (“mycobiome”) in healthy and diseased states. This
thesis explores the mycobiome in 1) healthy humans with a vegetarian diet and 2)
pediatric small bowel transplant recipients that develop fungal bloodstream infections.
The gut mycobiome from healthy adult humans with a vegetarian diet was
determined using two sequencing technologies and a commercially available probe-based
method. The use of three culture-independent methods demonstrated that the gut
mycobiome is best characterized using a combination of methods, as each method has
strengths, weakness, and biases. In addition, this study provides insight into the
allochthonous nature of fungal inhabitants in the gut and demonstrates that fungal
diversity in the gastrointestinal tract is diet related. It is apparent that a wide variety of
fungi can be identified from the human gastrointestinal tract.

Further, the intestinal mycobiome of seven pediatric small bowel transplant
recipients was characterized. Transplant patients are subject to multiple risk factors and
have a correspondingly high incidence of candidemia. Molecular typing methods were
used to assess whether candidemia in small bowel transplant recipients was acquired
endogenously (from their own gut microbiota) or exogenously. Our results suggest that
small bowel transplant patients are infected both by Candida colonizing their
gastrointestinal tract and from exogenous sources. Ultimately, these results underline the
importance of Candida surveillance in small bowel transplant institutes.
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“Never, never, never give up.”
― Winston Churchill
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PREFACE
This thesis is comprised of four chapters characterizing the fungal communities in
the gastrointestinal tract of healthy and diseased humans. A primary goal of this research
was to raise awareness of gut fungi and discuss methods to characterize this understudied
group of microorganisms. Chapter 1 provides a review of the current understanding of
the mycobiome of the human gastrointestinal tract. Chapter 2 provides a profile of the
gut mycobiome from healthy adults with a vegetarian diet using two culture-independent
sequencing methods and a commercially available fungal detection assay. In Chapter 3,
our efforts were aimed at surveying gut fungi populations in small bowel transplant
patients over time and determining the source(s) of yeasts causing life-threatening
bloodstream infections. Finally, Chapter 4 summarizes the impact of this work and
discusses the continual efforts needed to explore the role of the mycobiome in human
health and disease.
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CHAPTER 1
FUNGI OF THE HUMAN GASTROINTESTINAL TRACT: A REVIEW
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1.1 THE GASTROINTESTINAL MICROBIOTA
All surfaces of the human body exposed to the environment are colonized with
complex and diverse populations of microorganisms from all three domains of life [33].
A majority of the microbes colonizing the human host are harbored within the
gastrointestinal (GI) tract, making the GI tract home to one of the densest microbial
communities on Earth. Approximately 100 trillion microorganisms inhabit the human gut
and outnumber human host cells by a factor of 10 to 1 [214]. Sequencing an estimated 3.3
million human intestinal bacterial genes demonstrated the gut microbial genome is
approximately 150 times greater than the human genome [163]. This population of
microbes, collectively termed the gastrointestinal microbiota, has received much attention
and has been at the forefront of biological research for the last decade.
The acquisition of - and colonization by - microbes residing in the GI tract of
newborn infants is an emerging field of study. Traditionally, it was believed that the
gastrointestinal tract of neonates is sterile in utero and immediately becomes colonized
by microbes from their surroundings upon birth. However, recent culture-independent
research shows the placenta harbors a unique collection of nonpathogenic bacterial
commensals from the phyla Firmicutes, Tenericutes, Proteobacteria, Bacteroidetes, and
Fusobacteria [1]. Previous analyses also show bacteria and fungi are present in the
amniotic fluid, placenta, and umbilical cord [46, 91, 168]. In addition, bacteria such as
Staphylococcus, Streptococcus, Enterococcus, and Lactobacillus have been cultured from
the meconium, the newborns’ first passed stool [135]. Collectively, support for microbial
transmission from mother to fetus in utero has led to the ‘early programming hypothesis’
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stating that factors acting in utero program the risks for adverse health conditions later in
life [62].
The development of the infant’s intestinal microbiota begins early in life and
colonization order is greatly influenced by a number of lifestyle factors. Newborns are
first exposed to their mother’s microbiota, and depending of the mode of delivery,
vaginal or cesarean, their microbiota resembles the vaginal or skin microbiota of their
mother [5, 49]. In the subsequent days following birth, newborns are continuously faced
with a number of environmental factors that become major determinants of the
composition of the gut microbiota. Feeding mode is claimed to substantially affect the gut
microbiota. Breastfed infants (as compared to formula-fed infants) develop and establish
a microbiota rich in beneficial microbes such as Bifidobacterium by the end of the first
week [16, 76, 156, 226]. In addition, human breast milk contains secretory IgA and free
oligosaccharides that help develop the immune system and protect infants from
colonization by pathogens [123, 170]. Other extrinsic factors orchestrating the
development of the gut microbiota include the use of antimicrobial agents, hygienic
conditions, family structure, and home environment [4, 44]. Throughout the first year of
life, the infant intestinal tract evolves from a nearly sterile environment to a diverse
assemblage of microorganisms, where it will slowly begin to resemble the microbiota of
an adult and remain relatively stable.
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1.2 ROLE OF THE GASTROINTESINAL MICROBIOTA IN HEALTH AND
DISEASE
The gastrointestinal microbiota plays a central role in the well-being of the human
host and is therefore often termed ‘the forgotten organ’ [151]. The microbiota has a
profound functional role in energy harvest and digestion. Complex polysaccharides and
proteins that escape human digestion in the small intestine serve as the main substrates to
resident colonic microbes [39]. The microbiota breaks down these undigested nutrients
into the short-chain fatty acids (SCFA) acetate, butyrate, and propionate. SCFAs become
readily available to the human host and provide energy that would otherwise be lost.
Production of SCFAs has been shown to confer health benefits and decrease the risk of
colon cancer [73, 218]. In addition, the microbiota synthesizes vitamins essential to the
host [7].
The GI tract is the primary site of interaction between the human immune system
and microbiota and, therefore, is of substantial importance for immunological
development. Studies show the gut microbiota is responsible for the development of
immune cells such as secretory IgA and provides signaling molecules that aid in
maturation of the host immune system [128, 140]. In conjunction with the immune
system providing critical disease resistance and a line of defense against pathogens, the
gastrointestinal microbiota aids in limiting colonization by pathogens via a phenomenon
known as colonization resistance [206].
While commensal microbial communities in the gut carry out a series of
advantageous and essential functions, perturbation of the system creates a dysbiosis.
Dysbiosis refers to a microbial imbalance in the gut with increased levels of harmful
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microbes and reduced levels of beneficial microbes. Imbalances in the composition of the
microbiota have been associated with a number of digestive diseases such as ulcerative
colitis, Crohn’s disease, inflammatory bowel disease, irritable bowel syndrome, and
colon cancer [90, 120, 144, 160, 220]. In addition, recent research has indicated that
disruptions in the gut microbiome and relative abundances of certain members are
associated with complex, non-digestive diseases such as obesity, type 2 diabetes, chronic
fatigue syndrome, arthritis, liver disease, and autism [36, 54, 106, 115, 183, 189].
Determining what constitutes a healthy microbiota is essential for evaluating deviations
associated with disease.

1.3 DIVERSITY OF THE GASTROINTESTINAL MICROBIOTA
The gastrointestinal tract extends from the oral cavity to the anus with welldefined anatomical sections within. Each individual component of the GI tract has a
specialized function for the digestion and absorption of food. Microorganisms within the
digestive tract are not randomly distributed but instead are preferentially localized to
specific regions in different numbers and taxonomic distributions [117]. Properties of
each section in the digestive tract such as pH, rapid luminal flow, bile salts, and oxygen
availability are driving factors that shape microbial diversity by supporting or
discouraging growth [95, 210]. A majority of the gut microbiota is anaerobic, with a
lower proportion of facultative anaerobes and aerobes [64, 77].
Microbial numbers increase in a gradient from the stomach to the colon (Table
1.1). The upper gastrointestinal tract (stomach, duodenum, jejunum, proximal ileum)
contains a relatively low number of microorganisms. Very few organisms (<102
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cells/mL), consisting of acid-tolerant lactobacilli and streptococci, are present in the
stomach and upper small intestine due to harsh pH conditions [117]. Cell densities in the
proximal small intestine range from 104-105 cells/mL of intestinal content [210]. The
lower gastrointestinal tract (distal ileum, colon) contains a much higher population and
diversity of microorganisms—108 cells/gram in the distal ileum and approaching 10101012 cells/gram in the colon. Less acidic pH, low concentration of bile acids, and longer
retention due to slower peristalsis are several properties that distinguish the colon from
the rest of the GI tract and allow it to be the primary site of colonization [210]. Fecal
samples are, therefore, commonly used as a snapshot of the gut microbiome.

Table 1.1 Microorganism groups and counts in different sections of the
gastrointestinal tract [186].
Microorganisms

Stomach

Jejunum

Ileum

Colon

Aerobic and facultatively anaerobic microorganism groups
Enterobacteria

0-102

0-103

102-106

104-1010

Enterococci

0-103

0-104

102-106

105-1010

Staphylococci

0-102

0-103

102-105

104-107

Lactobacilli

0-103

0-104

102-105

106-1010

Fungi

0-102

0-102

102-103

102-106

Anaerobic microorganism groups
Bacteroides spp.

Rare

0-102

103-107

1010-1012

Bifidobacteria

Rare

0-103

103-105

108-1012

Anaerobic streptococci

Rare

0-103

102-104

108-1011

Clostridia

Rare

Rare

102-104

106-1011

Eubacteria
Rare
Rare
Rare
109-1012
Note: Figures in colony forming units (CFU) per mL or per g intestinal content.
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Lastly, the diversity of the microbiota is divided into two categories: indigenous
(autochthonous) and transient (allochthonous) microorganisms. Autochthonous
microorganisms are ubiquitous in the GI tract, readily colonize available niches, and are
stable over time, whereas allochthonous microorganisms cannot readily colonize the GI
tract [53]. Allochthonous species are merely transient members that are unable to
establish themselves in a foreign community. These species mainly originate from
consumption or ingestion of air and food or water. The distinction between
autochthonous and allochthonous microorganisms in the gut is crucial to understand how
organisms interact with their host in terms of whether they effect colonization and
succession [117].

1.4 COMPONENTS OF THE HUMAN GUT MICROBIOME
Bacteria are the most abundant members in the gut and, therefore, have
overshadowed the presence of other members of the gut microbiome. In fact, this
complex community of intestinal microbes spans all three domains of life - Bacteria,
Archaea, and Eukarya - and includes bacteria, protists, fungi, and viruses. Few studies
have investigated the contribution of microbial residents other than bacteria to function of
the human host.

1.4.1 PROKARYOTIC DIVERSITY
Over 99% of the genes in the human gut microbiome are of bacterial origin and
the number of bacterial species reported from the gut is generally believed to be between
500-1,000 [163, 221]. Fifty-five bacterial phyla have been described from the human gut;
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however, the two most dominant phyla are Bacteroidetes and Firmicutes [12, 55, 184].
Five other common phyla, present in lower proportions, are Proteobacteria, Fusobacteria,
Verrucomicrobia, Cyanobacteria, and Actinobacteria. One study involving fecal samples
from 124 Europeans showed each individual harbored at least 160 species of bacteria and
a majority of the species was shared among individuals [163].
Prokaryotic, single-celled members of the Kingdom Archaea reside alongside
bacteria in the gut [163]. The archaea, once considered bacteria, consist of halophiles and
thermophiles, found in extreme environments; and methanogens, found in a broad range
of habitats. Only a few methanogens are found in the human gut. Methanobrevibacter
smithii is considered the predominant archaeon; Methanosphaera stadtmaniae and
Methanobrevibacter oralis are also present in the gut [51, 131, 133, 181]. The carriage
rate of methanogens in the human gut ranges from 25-95% [51, 194]. Intestinal
methanogens play a role in the pathogenesis of obesity [132, 176, 225].

1.4.2 VIRAL DIVERSITY
One aspect of the human gut microbiome that has received little attention is the
viral component, referred to as the “human virome.” Human feces contain at least 109
eukaryotic and prokaryotic viruses per gram [167]. The adult virome consists of DNA
and RNA viruses, the majority being bacteriophages and plant viruses, respectively [25,
224]. Bacteriophages influence human health by contributing genes to their host bacteria
that affect overall community and structure of the microbiota [31]. Bacteriophage
repertoires vary widely between individuals and are likely the reason for inter-individual
variation in gut bacterial communities [134]. Eukaryotic viruses also have significant
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effects on human health, causing gastroenteritis and a host of acute, chronic, and fatal
diseases [32].

1.4.3 EUKARYOTIC DIVERSITY
Eukaryotes in the human gut are less extensively studied than prokaryotes, yet
remain an important component of the microbiome. The Domain Eukarya encompasses a
vast diversity of organisms spanning from animals, plants, and fungi to protozoa, slime
molds, and algae. A bulk of the eukaryotes found in the human gut, as expected, are
microeukaryotes and ignorance of these organisms becomes a major limitation of gut
microbiome studies.
Protista (now split into several kingdoms) comprises a collection of single-celled,
eukaryotic organisms including protozoa, unicellular algae, slime molds, and water
molds. Several protists are known to cause disease, however, few have been described as
asymptomatic commensals in the gut [22, 162]. Studies show that the protist Blastocystis
and fungi are the dominant eukaryotes in the gut [142, 180]. Also, the protists
Blastocystis and Dientamoeba have been observed in 50% of some Danish cohorts, and
are nearly absent in those with inflammatory bowel disease [8]. Although protists make
up a small component of the microbiome, further research is necessary to understand
their role in health and disease.
Fungi are eukaryotic organisms that can occur as single-celled yeasts,
multicellular filamentous molds, or macroscopic organisms such as mushrooms, and
range from pathogens to commensals and parasites to mutualists. Populations of fungi
colonize the human host at multiple different body sites—gastrointestinal tract, oral
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cavity, skin, vaginal tract, and lungs (Figure 1.1) [50, 58, 63, 80, 207]. Most humanassociated fungi are opportunistic pathogens in that disease is caused when the host
immune system becomes weakened or natural barriers are disrupted. Well-known fungal
infections range from skin mycoses such as athlete’s foot, ringworm, and yeast
infections, to more life-threatening systemic mycoses caused by Cryptococcus, Candida,
and Aspergillus. An estimated 75% of women will encounter a yeast infection during
their lifetime and roughly 20-25% of the world's population has skin mycoses [79, 190].
Fungi represent the majority of eukaryotes in the human gut microbiome and the
remaining sections of this review detail and depict what is currently known about the
relatively new field of human gut mycology.
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Figure 1.1 The human mycobiota [204].

1.5 THE HUMAN GASTROINTESTINAL MYCOBIOME: A NEW FRONTIER
Gut bacteria are the most abundant microorganisms in the gastrointestinal tract, and
therefore, have been the focus of much human microbiome research over the past decade.
The extent of biodiversity of the “mycobiome” (fungal biota) in the human
gastrointestinal tract remains to be defined. The term mycobiome was coined in 2010 to
differentiate the fungal biota from the bacterial biota, as the word “microbiota” is
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frequently treated as synonymous with bacteria [63]. On July 6, 2013, using a PubMed
search, the word “mycobiome” appeared in the literature 10 times [38]. As of March 6,
2015 a PubMed search showed at least 32 publications using the word “mycobiome.” The
field is clearly advancing and increasing awareness allows gut microbiologists to address
the same questions to gut fungi as have been studied in bacteria.

1.5.1 HISTORY
Yeasts were first identified in the human GI tract in the early nineteenth century
[104]. However, at the time no effort was made to identify and characterize these yeasts.
In the early 1900s, the presence of yeasts in feces was sporadically documented in the
medical literature and studies tried to link their presence to gastrointestinal diseases, such
as sprue (a digestive disease characterized by malabsorption and commonly reported in
tropical regions) [13, 23, 109]. Years later, just before World War II, isolates from human
clinical samples were identified as yeasts of the genus Monilia, which were later
reclassified into the genus Candida [105, 121, 122]. Culturing Candida from the
intestines of healthy humans and those with gastrointestinal disturbances became a
popular area of research during the mid-1900s. Candida was the most commonly isolated
yeast from fecal samples, yet its significance and occurrence in stools had yet to be
elucidated due to the fact that heavy loads of Candida species were collected from
healthy humans [23].
The long known history of yeasts in the gastrointestinal tract and their peculiar
presence led physicians in the late 1980s to propose hypotheses linking unhealthy
lifestyles to Candida overgrowth in the intestine [186, 202]. Mycophobia was also
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spreading due to falsely interpreting yeasts isolated from the mouth or stool as fungal
infections [187]. Gut mycology has therefore become a field in need of attention and
advancement.

1.5.2 GASTROINTESTINAL COLONIZATION BY FUNGI
As stated previously, microbial colonization starts at birth. The vaginal tract is
home to a large number of yeasts and, not surprisingly, neonates born vaginally are
colonized by yeasts from their mother’s vaginal microbiota [21]. Infant colonization by
Candida spp. is therefore transmitted vertically from the maternal microbiota and also
horizontally from the environment and hands of health care workers [21, 116]. The
prevalence of Candida spp. gut colonization in newborns on the day of birth is roughly
23%, increasing to 50% by four months [56, 174]. Yeast carriage rates in infants are
approximately 103-105 CFU/g feces [16, 56]. Additionally, 96% of neonates have
detectable Candida species in the oral cavity by the first month of life [171].
Every human being is colonized with fungi [85]. Fungi are detectable in all
sections of the GI tract of about 70% of healthy adults, normally at 0-103 fungal cells per
ml or g of intestinal contents [186]. Table 1.1 (above) shows the relative abundance of
fungi in each section of the gut and outlines the disparity that exists between fungal and
bacterial residents of the GI tract. Culture-independent analyses show fungal genes
constitute less than 0.1% of the human gut microbiome [163]. The low abundance of
fungi in the gut microbiome undoubtedly relegates them to part of the ‘rare biosphere’
[191]. The rare biosphere is of significance as it potentially serves as a reservoir for
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pathogens or keystone species that have a critical role in maintaining the structure and
function of the human gut microbiome [85].
The oral cavity is asymptomatically colonized by Candida and harbors a wide
diversity of fungi, likely from food and airborne spores [11, 63]. The rapid luminal flow
and low pH of gastric acid allows few microorganisms to colonize the stomach and
functions as a barrier to prevent ingested pathogens from reaching the intestine [124]. A
number of acid-resistant bacteria exist in the stomach as well as a few acid-tolerant fungi
such as Candida and Phialemonium [19, 208]. The diversity of fungi in the small
intestine is largely unexplored due to the difficulty in collecting samples [211]. Ileal
effluent collected from intestinal transplant recipients showed colonization by
Saccharomyces cerevisiae, Candida spp., Cryptococcus neoformans, and Aspergillus
clavatus [112]. The properties of the large intestine facilitate extensive microbial
colonization and proliferation, and a wide diversity of fungal genes is detected in the
lower gastrointestinal tract.

1.5.3 FUNGAL DIVERSITY OF THE INTESTINAL MYCOBIOME
Two large-scale projects, the Human Microbiome Project and MetaHit, provide
an initial compilation of the gut microbiome ecosystem from 242 and 124 humans,
respectively [86, 158, 163]. As revealing as the results have been, publications to date
from these projects focused exclusively on the bacterial component and the fungal
diversity was not considered. Smaller-scaled, fungal-specific studies using culturedependent and/or culture-independent methods have thus been conducted but are limited.
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Previous culture-dependent studies identified Candida spp. as the most common
fungi in the GI tract. With the development of advanced culturing methodologies and
PCR, the modern era of mycobiome studies has exposed a more in-depth survey of both
culturable and unculturable fungi in the gut. At present only a handful of mycobiome
characterization studies exist. To the best of our knowledge, we compiled a
comprehensive list of fungal species reported from the GI tract of humans by culturedependent and culture-independent studies (Table 1.2; includes: healthy and diseased
adults and infants, fungi from stomach, small intestine, large intestine, differing diets and
varying geographic locations). Data was compiled December 2014 from articles spanning
1917-2014. Also, included in the list are fungi detected in our lab from healthy humans
on a vegetarian diet reported in Chapter 2 of this thesis (denoted S in Table 1.2). If a
more current name for a fungus exists than that used in the initial publication, the current
name is also listed. Fungi reported from the literature but not specified to the species
level are excluded from the list if a species from that genus, family or class is listed. Taxa
reported in the literature that are indistinguishable from one another at the level of the
target gene used are listed in the same row.

Table 1.2 Comprehensive catalog of fungi reported in the gastrointestinal tract of
humans by culture-dependent and -independent methods.
Phylum

Fungal Taxa

Ascomycota

Ajellomyces capsulatus [112], Current name: Histoplasma capsulatum
Ajellomyces dermatitidis [112]
Alternaria alternata [68, S], A. brassicicola [113], A. arborescens, A. citri,
A. mali, A. tenuissima [S]
Amphisphaeriaceae sp. [48]
Arxiozyma telluris [75], Current name: Kazachstania telluris
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Ascocoryne cylichnium [S]
Ascocoryne sarcoides [S]
Aspergillus clavatus [112, 113]
Aspergillus flavipes1 [66]
Aspergillus flavus1 [67], Aspergillus oryzae [S]
Aspergillus fumigatus [203, S]
Aspergillus microviridicitrinus1 [34]
Aspergillus niger2 [34, 74, 199, S]
Aspergillus penicillioides [30]
Aspergillus restrictus [68]
Aspergillus sydowii1 [199], Aspergillus versicolor2 [30, 34, 66, 180, 199]
Aureobasidium pullulans2 [30, 152, 198]
Beauveria bassiana1 [66]
Bispora christiansenii [68], Current name: Intralichen christiansenii
Blastoschizomyces capitatus1 [97] (also reported as Dipodascus capitatus,
[203]) Current name: Geotrichum capitatum
Botryotinia fuckeliana [112, 152], Current name: Botrytis cinerea
Candida albicans2 [6, 10, 18, 30, 34, 46, 59, 60, 68, 74, 92, 97, 108, 112,
113, 118, 152, 153, 180, 192, 195, 198, 208, S] (also reported as
Endomyces albicans1 [9], Oidium albicans1 [9], Parasaccharomyces
ashfordii1 [9])
Candida colliculosa1 [10, 18]
Candida diddensiae [108]
Candida dubliniensis [68, 112, 113, 152]
Candida glabrata2 [6, 18, 30, 68, 92, 97, 108, 118, 152, 195] (also reported
as Cryptococcus glabratus1 [9], Torulopsis glabrata1 [34])
Candida guilliermondii1 [6, 10, 34, 97], Current name: Blastodendrion
artzii
Candida inconspicua1 [10]
Candida intermedia [10, 30]
Candida kefyr1 [6, 18, 92], Current name: Atelosaccharomyces
pseudotropicalis
Candida krusei1 [6, 10, 18, 30, 34, 75, 97, 118, 198] (also reported as
Mycoderma monosa1 [9]), Current name: Candida acidothermophilum
Candida lambica1 [97], Current name: Candida fimentaria
Candida lusitaniae2 [6, 10, 18, 28, 97] (also reported as Clavispora
lusitaniae2 [68])
Candida metapsilosis [74]
Candida milleri [30], Current name: Candida humilis
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Candida norvegensis [6], Current name: Candida mycoderma var.
annulata
Candida quercitrusa [108]
Candida orthopsilosis2 [10, 28]
Candida parapsilosis2 [10, 18, 28, 34, 74, 97, 108, 112, 118, 180, 198, 199,
208]
Candida pelliculosa1 [10], Current name: Candida beverwijkiae
Candida rugosa2 [74, 75, 97) (also reported as Mycoderma rugosa1 [9])
Candida sake [74, 203] (also reported as Candida austromarina [30, 152])
Candida solani [30]
Candida sphaerica1 [6, 10]
Candida stellata1 (reported as Torulopsis stellata [34])
Candida temnochilae1 [10]
Candida tropicalis2 [6, 10, 18, 28, 30, 34, 66, 74, 97, 108, 112, 113, 198,
203, S] (also reported as Monilia candida Bon. [9, 208])
Candida utilis1 [6, 10], Current name: Candida guilliermondi var.
niratophila
Candida valida1 [10], Current name: Candida krusei var. vanlaeriana
Candida vinaria [142], Current name: Trigonopsis vinaria
Candida zeynaloides1 [6] (also reported as Candida krissii [30])
Ceratocystis sp. [80]
Chaetomium globosum [30, 42, 152]
Cladosporium cladosporioides2 [28, 34, 108, 152, S], C. bruhnei [67], C.
herbarum1 (= Davidiella tassiana [68, 74, 198]), C. macrocarpum1 [198],
C. sphaerospermum2 [108, 198, 199], C. tenuissimum [108]
Claviceps purpurea [48]
Coccidioides immitis [112]
Coccidioides posadasii [112]
Cochliobolus sp. [80]
Colletotrichum sp. [80]
Coniosporium sp. [80]
Cryptococcus aggregatus1 [9], Current name: Candida pararugosa
Curvularia lunata1 [34]
Cyberlindnera jadinii [S] (also reported as Pichia jadinii [74])
Debaryomyces carsonii1 [10], Current name: Priceomyces carsonii
Debaryomyces fabryi [28]
Debaryomyces hansenii2 [28, 48, 68, 74, S] (also reported as Candida
famata1 [6, 92]
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Dendrostilbella sp. [110]
Diaporthales sp. [108]
Didymella exitialis [74]
Diplodia mutila [S]
Doratomyces stemonitis [30]
Epicoccum nigrum [S]
Eurotium niveoglaucum [S]
Eurotium rubrum [S] (also reported as Aspergillus ruber1 [67])
Eutypella sp. [80]
Exophiala equina [68]
Exophiala heteromorpha [S]
Fusarium graminearum [S], F. culmorum [74]
Fusarium oxysporum [112, 152]
Fusarium sambucinum [74]
Galactomyces geotrichum2 [30, 66, 68, 74, 75, 152, 180]
Geosmithia flava [74]
Geosmithia microcorthyli [74]
Geotrichum candidum2 [75, 97] (also reported as Galactomyces candidum
[68])
Geotrichum gigas [74], Current name: Saprochaete gigas
Gibberella moniliformis [113]
Gloeotinia temulenta/Paecilomyces fumosoroseus [180]
Glomerella sp. [74, 80]
Hanseniaspora sp. [80]
Hortaea werneckii [28]
Hyphozyma variabilis var. odora [30]
Iodophanus carneus [30]
Isaria farinosa1 [66]
Kluyveromyces hubeiensis [75, 153]
Kluyveromyces lactis [42]
Kluyveromyces waltii [112], Current name: Lachancea waltii
Lasiodiplodia sp. [80]
Lecythophora sp. [S]
Leptosphaerulina chartarum [S]
Lodderomyces elongisporus1 [10]
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Madurella mycetomatis [152]
Magnaporthe grisea [42]
Metschnikowia sp. [74, 80]
Meyerozyma sp. [80]
Microdochium sp. [80]
Millerozyma sp. [80]
Mycocentrospora sp. [80]
Nectria haematococca [42], Current name: Haematonectria haematococca
Neofusicoccum sp. [80]
Neosartorya fischeri [42, S]
Neotyphodium gansuense [113]
Neurospora tetrasperma [113]
Nigrospora sp. [80]
Ochrocladosporium elatum1 (reported as Cladosporium elatum [198])
Ophiocordyceps caloceroides [30], Current name: Cordyceps caloceroides
Ophiocordyceps sinensis [S]
Ophiostoma sp. [80]
Orbiliales sp. [108]
Paecilomyces variotii1 [34]
Paraphaeosphaeria filamentosa [152], Current name: Neophaeosphaeria
filamentosa
Parasaccharomyces thomasii1 [9]
Penicillium allii1 [66], P. camemberti2 [66, S], P. chrysogenum2 (=
Penicillium notatum) [34, 68, 113, 152, 199, S], P. commune [203], P.
dipodomyicola1 [66], P. freii [30], P. italicum [152], P. solitum [67]
Penicillium brevicompactum1 [66]
Penicillium chermesinum1 [34]
Penicillium citrinum1 [199]
Penicillium decumbens1 [199]
Penicillium glabrum [152]
Penicillium marneffei [112]
Penicillium ochrochloron1 [34]
Penicillium roqueforti [74, 180, 203, S]
Penicillium sacculum [152]
Penicillium steckii1 [199]
Penicillium turbatum [S]
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Penicillium verruculosum [152]
Phaeococcomyces sp. [80]
Phaeosphaeria nodorum [113]
Phaeosphaeria pontiformis [74]
Phialemonium sp. [208]
Phialocephala lagerbergii [S]
Phoma sp.1 [110]
Pichia kudriavzevii [S]
Pichia manshurica1 [10]
Plenozythia sp.1 [110]
Pleospora herbarum [152]
Podosphaera xanthii [S]
Pseudosaccharomyces stevensii1 [9]
Raciborskiomyces longisetosus [152], Current name: Epipolaeum
longisetosum
Ramularia sp. [74]
Saccharomyces bayanus [28, 152]
Saccharomyces cariocanus [152]
Saccharomyces castellii [112, 113], Current name: Naumovia castellii
Saccharomyces cerevisiae2 [6, 10, 28, 30, 42, 67, 68, 74, 75, 92, 108, 112,
113, 118, 142, 152, 180, 203, S]
Saccharomyces paradoxus [30]
Saccharomyces servazzii [142], Current name: Kazachstania servazzii
Scedosporium apiospermum [74]
Scheffersomyces stipites [42]
Sclerotinia sclerotiorum [68, 112, 113, 152]
Sclerotium sp. [67, 152]
Scopulariopsis sp. [42]
Scytalidium thermophilum [74]
Septoria epambrosiae [152]
Simplicillium lanosoniveum [30]
Simplicillium obclavatum [30]
Sirococcus conigenus [152]
Stemphylium sp. [80]
Sterigmatomyces elviae [75]
Strelitziana sp. [80]

21
Talaromyces stipitatus [42]
Teratosphaeria sp. [80]
Torula nigra1 [110]
Torulaspora pretoriensis [75]
Toxicocladosporium sp. [80]
Trichocladium asperum [74]
Trichoderma lignorum1 [34], Current name: Trichoderma viride
Trichoderma longibrachiatum [S]
Trichophyton verrucosum [112]
Verticillium leptobactrum/Verticillium insectorum [180]
Westerdykella cylindrical [68]
Xeromyces sp. [80]
Xylariales sp. [108]
Yarrowia lipolytica2 [42, 68, 97, 152]
Zygosaccharomyces bisporus [9]
Zygosaccharomyces rouxii [28]
Basidiomycota

Agaricus bisporus [48, S]
Armillaria sp. [80]
Asterophora parasitica [75]
Asterotremella albida (nom. inval.) [30], Current name: Sporobolomyces
albidus
Auricularia sp. [80]
Bjerkandera adusta [75]
Bullera crocea [152], Current name: Dioszegia crocea
Ceriporia lacerate [74]
Chondrostereum sp. [80]
Cinereomyces sp. [80]
Climacocystis sp.1 [66]
Clitopilus prunulus [68]
Cryptococcus albidosimilis [108]
Cryptococcus albidus1 [97]
Cryptococcus amylolyticus [S]
Cryptococcus carnescens [152]
Cryptococcus fragicola [30]
Cryptococcus humicola (reported as Candida humicola [28])

22
1

Cryptococcus laurentii [34]
Cryptococcus luteolus1 [97], Current name: Hannaella luteola
Cryptococcus neoformans [112, 113]
Cryptococcus ovoidea1 [9]
Cryptococcus podzolicus [108]
Cryptococcus tephrensis [74, S]
Cystofilobasidium capitatum2 [67, 152]
Dacrymyces sp. [152]
Erythrobasidiaceae sp. [74]
Exidiopsis calcea [152]
Exobasidiomycetes sp. [80]
Filobasidium capsuligenum [68]
Filobasidium globisporum [68, 152]
Flammulina velutipes [152]
Fomes fomentarius [68]
Fomitopsis pinicola [68, 152]
Fuscoporia gilva [74]
Graphiola phoenicis [152]
Hymenochaete sp. [80]
Hypholoma sp. [80]
Laccaria bicolor [113]
Lentinus sp. [80]
Malassezia globosa2 [28, 42, 66, 67, 68, 75, 112, S]
Malassezia pachydermatis2 [30, 66, 67, 68, 75, S]
Malassezia restricta2 [28, 66, 67, 68, 74, 75, S]
Malassezia slooffiae [S]
Malassezia sympodialis [74, S]
Moniliophthora perniciosa [42, 113], Current name: Crinipellis perniciosa
Mrakia sp. [74, S]
Oidium lactis1 [9], Current name: Oospora lactis
Phanerochaete stereoides [75]
Phlebia nitidula [74]
Phlebia uda [74], Current name: Mycoacia uda
Pholiota sp. [S]
Piptoporus sp. [80]
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Postia placenta [42], Current name: Rhodonia placenta
Psathyrella candolleana [180]
Puccinia poarum [68]
Rhodosporidium babjevae [68]
Rhodotorula aurantiaca [152]
Rhodotorula glutinis1 [97] (also reported as Saccharomyces glutinous1 [9])
Rhodotorula minuta1 [34]
Rhodotorula mucilaginosa2 [34, 68, 152]
Sporobolomyces ogasawarensis [153]
Sporobolomyces yunnanensis [152]
Thanatephorus sp. [80]
Tilletiopsis washingtonensis [74]
Torula rubra1 [9], Current name: Rhodotorula rubra
Trametes versicolor [152]
Trichaptum sp. [80]
Tricholoma saponaceum [152]
Trichosporon asahii2 [10, 68, 75]
Trichosporon caseorum [75]
Trichosporon cutaneum [75]
Trichosporon dermatis [28, 152]
Trichosporon faecale [68]
Trichosporon guehoae [74]
Tyromyces sp. [80]
Ustilago maydis [42, 152]
Wallemia muriae [30, S]
Wallemia sebi [30, 48]
Chytridiomycota Spizellomyces punctatus [113]
Microsporidia

Enterocytozoon bieneusi [42]

Zygomycota

Entomophthora sp. [48]
Mucor racemosus [153]
Rhizopus microsporus [28]

Syncephalastrum racemosum1 [34]
Note: No superscript indicates fungi were detected by culture-independent method.
1
Fungi were detected by culture-dependent method.
2
Fungi were detected by both culture-dependent and -independent methods.
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The most commonly detected fungi in the GI tract of humans among the 36
studies listed in Table 1.2 are C. albicans (25 studies), Saccharomyces cerevisiae (19), C.
tropicalis (17), C. parapsilosis (13), C. glabrata (12), C. krusei (10), Malassezia globosa
(8), M. restricta (7), and Debaryomyces hansenii (7). Candida species are known to
dominate the GI tract of humans and their presence is not surprising. To the best of our
knowledge, at least 268 fungal taxa have been reported in gut, which is considerably
lower than the estimated 500-1,000 bacteria residing in the gut [163, 221]. Additionally, a
majority of the fungi were only reported in one study.

1.5.4 STABILITY OF THE MYCOBIOME
Fungi residing in the gastrointestinal tract can originate from a number of sources.
Fungi are ubiquitous in the environment and are used as food and in food production,
making their presence in the gut a reflection of the individual’s diet and environmental
encounters [180]. DNA extracted from food and fecal samples show that foodborne fungi
from the diet transiently colonize the gut [42]. Species of fungi found in the gut known to
colonize the skin and respiratory tract are also thought to be transient members [98]. Due
to the transient and allochthonous nature of numerous fungal members in the gut, stability
of the gut mycobiome over time is low [74]. Table 1.2 also illustrates the dynamic and
variable nature of the mycobiome in the number of fungi identified in a single study.
Fungal populations in the murine gut vary substantially over time and are influenced by
the environment, while bacterial populations remain relatively stable [47]. There are both
more bacterial species and more individual bacteria in the gut than fungi and thus,
bacterial communities may be more robust [204].
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1.6 MEDICALLY RELEVANT FUNGI: PATHOGENIC YEASTS
Fungal diseases, especially those caused by opportunistic pathogens, have become
increasingly important over the past few decades. The success of modern medicine and
the explosion of new antibacterial agents have led to greater survival of
immunocompromised patients while creating populations highly susceptible to fungal
infections. The most common yeasts found associated with disease are Candida,
Histoplasma, Blastomyces, and Cryptococcus and to a lesser extent species of
Geotrichum, Malassezia, Pichia, Rhodotorula, Saccharomyces, and Trichosporon. With
the exception of Blastomyces, each of these fungal genera has been reported in the GI
tract. The most common filamentous fungi associated with disease found in the gut are
Aspergillus spp. Additionally; other fungi found in the gut and causing infections include
Alternaria, Scedosporium, Paecilomyces, and Trichoderma.

1.6.1 CANDIDA SPECIES
Candida species are normal, harmless commensals on many human body sites
and have been consistently reported in gut fungi studies. C. albicans is the predominant
commensal yeast of humans. Candida spp. are also opportunistic pathogens of humans
and cause disease when mucosal barriers are disrupted and defects in the immune system
occur. They can invade and cause infections ranging from superficial infections of the
skin to life-threatening systemic infections. At least 17 Candida species, out of the
approximately 150 known species, cause disease in humans, the most common being
Candida albicans, C. dubliniensis, C. glabrata, C. guilliermondii, C. krusei, C.
lusitaniae, C. parapsilosis, and C. tropicalis [139]. Recent studies show that Candida
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spp. are the fourth most-common cause of nosocomial bloodstream infections [216, 217].
An estimated 60,000 cases of disseminated candidiasis occur each year in the U.S, with
an estimated cost of 2-4 billion dollars [157, 215].
In the years prior to 1990, the predominant species causing invasive Candida
infections was C. albicans [157]. C. albicans lacks an environmental reservoir and is
almost exclusively associated with humans and possibly other warm-blooded animals and
avian species [26, 89, 119, 169]. C. albicans is considered the most virulent species of the
genus Candida because it contains an arsenal of virulence factors and fitness attributes
that contribute to pathogenesis. The most widely studied virulence factors include
adhesins, secreted hydrolytic enzymes, and morphogenesis.
Adherence to the host cell is an essential first step of pathogenesis. C. albicans
expresses adhesins on the surface of the cell that allow it interact will host cells and
ultimately colonize host tissues. The agglutinin-like sequence (ALS) protein family
contains the most recognized C. albicans adhesins and consists of eight large cell-surface
glycoproteins for adherence to mammalian cells [83]. In addition to host cell adherence,
Candida species produce three-dimensional structured microbial community biofilms
surrounded by a matrix of exopolymeric material on biotic and abiotic surfaces [102,
165]. The formation of Candida biofilms becomes important clinically because of
biofilms’ increased resistance to antifungals and protection from host immune defenses
[14]. Biofilms forming on implanted medical devices such as catheters, shunts, prosthetic
devices, and dentures serve as a reservoir for infection and direct access to the body
[164].
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Extracellular proteolytic activity is another C. albicans pathogenicity mechanism.
The best-characterized Candida proteases are the secreted aspartyl proteinases (Sap)
[136, 137]. Sap proteins help digest molecules for nutrient uptake, distort host cells to
enable adhesion and tissue invasion, and digest components of the host immune system to
evade attack [141]. In vitro models using sap deletion mutants show attenuated virulence
and demonstrate Sap proteins contribute to the overall virulence and are required for
disseminated infection [84, 177, 182].
Morphological switching is a virulence strategy used by C. albicans to aid in its
pathogenic potential. When C. albicans comes into contact with a surface, yeast cells
transition into hyphal forms [103]. Both morphological forms are important for
pathogenicity; the hyphal form aids in cellular invasion and the yeast form is primarily
involved in dissemination [17, 179]. Quorum sensing regulates the yeast-to-filamentous
transition in C. albicans by molecules by farnesol [82]. C. albicans also has a range of
fitness attributes that allow the yeast to adapt to pH changes, stress, and nutrient
starvation [127].
In recent years, there has been an increased prevalence of infections caused by
species of Candida other than C. albicans. The introduction and widespread use of
antifungals has led to an increased number of infections caused by C. glabrata, due to its
resistance to fluconazole, itraconazole, and moderate (dose-dependent) resistance to other
antifungal agents [201]. Distribution of Candida infections varies among countries and
institutions; C. glabrata is considered the second most common cause of Candida
infections in the U.S. and Europe, yet ranks behind C. parapsilosis and C. tropicalis in
South America and Asia, respectively [35, 107, 159, 197]. Reasons for geographical
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differences are of interest and outline the complexity of epidemiology. Multiple risk
factors including clinical practice, antifungal therapies, and colonization of health care
workers likely support the emergence of non-albicans species as predominant pathogens
[150].

1.6.2 ASPERGILLUS SPECIES
Invasive aspergillosis (IA) has increased significantly in recent decades and is the
most common filamentous fungal lung infection in immunocompromised patients [69,
130]. Aspergillus species have a worldwide distribution and their ubiquity in the
environment exposes humans to Aspergillus spores daily. Aspergillus fumigatus is the
most prevalent species of the 200 aspergilli described and is the main cause of human IA
[40]. A. flavus, A. glaucus, A. niger, A. nidulans, A. parasiticus, and A. terreus are also
commonly associated with aspergillosis [138]. Aspergillus species are also well known
for their ability to produce carcinogenic mycotoxins, aflatoxin, and ochratoxin, and show
resistance to some antifungals [45, 94]. Numerous species of Aspergillus have been
reported in the GI tract of humans (Table 1.2).

1.7 CHARACTERIZATION OF THE GASTROINTESTINAL FUNGAL
COMMUNITY
The correct identification of fungi is of great importance in clinical settings, and
especially in novel studies attempting to characterize microbial communities from
different ecological niches, such as the gastrointestinal tract. Methods for exploring and
characterizing the microbiota from the GI tract have greatly evolved over time. Wide
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ranges of techniques are available to identify fungi, all differing in specificity,
reproducibility, time, and cost. While each method has its own advantages and
limitations, advances over the years have improved our understanding of the human GI
tract ecosystem.

1.7.1 Culture-dependent methods
The first studies identifying the fungi of the gastrointestinal tract date back to the
early 1900s [9, 99]. The ability to culture fungi was critical for discovering and
identifying their presence. At the time it was known that feces contain a large number of
bacteria compared to fungi and ordinary culture medium and plating methods would not
be sufficient for the isolation of fungi from the gut. Therefore media inhibiting bacterial
growth, such as Sabouraud’s agar, were commonly used [9, 13]. Historically,
identification and classification of yeasts was based on readily observable gross colony
features (color, size, shape), microscopic examination, and biochemical properties. Over
time, culture-dependent methods including selective media, nutrient utilization and
fermentation, susceptibilities to yeast killer toxins, susceptibilities to chemicals and
antifungal drugs, secondary metabolites, fatty acid composition, cell wall composition,
and protein composition have been indispensable for increasing our understanding and
classifying fungi [70].
Although advancements have been made in culture-dependent methods, these
methods present several disadvantages and study limitations that restrict the ability for
mycologists to accurately characterize fungi in fecal samples. In culture-based studies,
dominant populations (e.g. Candida spp.) can mask the detection and diversity of low-
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abundance organisms. In addition, current fungal culture techniques may be inadequate to
optimally cultivate organisms that require microbe–microbe interactions, since culture
fails to reproduce ecological niches and symbiotic relationships encountered in the
natural environment [15, 29]. The culturable fraction is also distorted because replication
times vary among microorganisms and fast-growing species efficiently outcompete
others [143].

1.7.2 Culture-independent methods
Considering the above limitations of culture-dependent methods, the advent of
culture-independent methods has allowed researchers to more efficiently characterize the
mycobiome. In particular, the development of polymerase chain reaction (PCR) in the
1980s revolutionized culture-independent fungal detection methods [173]. In the ensuing
years, the introduction of multiple culture-independent DNA-based methods for
characterizing the gut microbiota became available—denaturing gel gradient
electrophoresis (DGGE), oligonucleotide fingerprinting of ribosomal RNA genes
(OFRG) and restriction fragment length polymorphism (RFLP). While these methods
have improved the ability to study the mycobiota, they still have a reduced ability to
identify fungi at the species level and quantify taxa [38].
The advent of high-throughput DNA sequencing technologies has become the
preferred method for mycobiome studies [48, 185]. Sanger sequencing and, more
recently, next-generation amplicon sequencing are capable of distinguishing species
using genes within the fungal ribosomal RNA gene cluster—18S small subunit rDNA,
28S large subunit rDNA, and the internal transcribed spacer (ITS1 or ITS2) (Figure 1.2).
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rRNA genes are appealing targets for fungal identification because they are highly
multicopy in each genome. Fungal rRNA genes have highly conserved regions serving as
primer binding sites to determine the sequences of adjacent variable regions by PCR
amplification. In fungi, 28S provides much greater resolution than 18S, and continues to
be used for within-genus (i.e., species-level) identification and phylogenetic studies,
while 18S is rarely adequate to distinguish species [41] (in contrast with the analogous
bacterial 16S gene, which is widely used for identification). ITS genes are less conserved
and, therefore, are considered the best target for fungal species and subspecies
identification [161]. Also, researchers must select which ITS gene (ITS1, ITS2 or ITS15.8s-ITS2) to amplify for identification (Figure 1.2). Next-generation sequencing of these
genes has provided the most accurate account of the fungal composition of the human gut
microbiome.
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A)

B)

Figure 1.2 Schematic representation of the A) fungal ribosomal gene cluster and B)
28s nuclear large rDNA with binding locations of PCR primers
(http://nature.berkeley.edu/brunslab/; accessed February 2015).

1.7.3 Culture-dependent vs. culture-independent methods
Few studies have used a combination of culture-dependent and -independent
methods for the identification of gut fungi and compared the results. One study exploring
the diversity of gut eukaryotes in a Senegalese man identified 16 fungal species by
molecular methods targeting the ITS, 18s, and 28s genes and only four fungal species by
culturing, using three culture media [75]. Three of the four fungi isolated by culture were
also detected by sequencing; the exception was C. krusei. An earlier gut fungi study using
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culture-dependent and -independent methods also highlighted a culturing bias. Candida
spp. were identified as the predominant species by cultivation methods and
Gloeotinia/Paecilomyces and Galactomyces were found to be the predominant species
using clone libraries [180]. Chen and colleagues found 37 fungal OTUs using clone
libraries while only five species, from two genera (Candida and Saccharomyces), were
isolated by two culture media [30]. The culture-independent method in this study failed to
detect C. krusei and C. glabrata.

1.8 THE GUT MYCOBIOME IN HEALTHY AND DISEASED STATES
1.8.1 Benefits of intestinal fungi
Compared to the vast amount of literature on the benefits of bacteria in the human
gut, the beneficial role of gut fungi – if any – remains largely unexplored. No strong
evidence exists for a mutualistic or beneficial relationship with the gut mycobiome [85].
The only fungus studied in any detail with indications of treating gastroenteritis is the
probiotic yeast Saccharomyces cerevisiae var. boulardii (“S. boulardii”) [222]. Clinical
trials using S. boulardii as a therapeutic strategy have shown significant efficacy in
treatment and prevention for various types of diarrhea including traveler’s diarrhea,
antibiotic associated diarrhea, and inflammatory bowel disease [24, 71, 72, 129]. In
addition to the presumed health benefits, it is proposed that probiotic yeasts may
positively interact with probiotic bacteria by enhancing their survival, and overall display
a synergistic effect [20, 196]. Another potential medical application of probiotic yeasts
involves their ability to express disease-fighting proteins known as killer toxins, or
mycocins, against pathogenic yeasts, such as Candida spp. [212].

34
1.8.2 Mycobiome and disease
Since the renowned Greek physician Hippocrates first described oral candidiasis
in 400 BC, researchers and clinicians have aimed to explore the roles of commensal and
pathogenic fungi in human health and disease [3]. In particular, cataloging the gut
mycobiome in health and disease has been a biological hot spot in recent years. Defining
fungi present and/or absent as well as alterations in the fungal community in the gut
during different disease states may inform knowledge of cause and effect. Do these fungi
contribute to or protect from disease? Do they cause disease directly or indirectly?
Gastrointestinal colonization by fungi such as C. albicans is suggested as the
major reservoir and source of invasive fungal infections such as invasive candidiasis
[148]. C. albicans, the predominant gut fungus, colonizes the GI tract but has the ability
to invade tissues and disseminate in the body when the gut microbiome is disrupted,
intestinal mucosal permeability is increased, or the host is immune-suppressed. Candida
gut colonization has been associated with a number of diseases such as diabetes,
hematologic malignancies, Crohn’s disease, and graft-versus-host disease; and patient
populations such as hospital inpatients and extremely low birth weight infants (Table
1.3). Patients with gastrointestinal disorders such as ulcerative colitis and Crohn’s disease
are more frequently and heavily colonized by C. albicans than are control groups [100,
193].
In the gut, the disease states studied thus far exhibit associations between fungal
diversity and disease. This has been demonstrated in patients with Crohn’s disease,
hepatitis B, and pouchitis [30, 101, 113, 152]. In many of these cases, fungal diversity is
positively correlated with disease progression and severity. However, this is not the case
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for the mycobiome at other diseased body sites. The human lung, previously thought to
be sterile, harbors a lower diversity of fungi in patients with cystic fibrosis than healthy
controls [78]. This is also true in the nasal mycobiome of allergic patients [188]. Drawing
broad conclusions about fungal diversity, colonization, and disease is difficult due to the
low number of studies, sample numbers, and uncertainty across body sites. Gut fungi data
indicates a role for the mycobiome in the pathogenesis of a number of diseases and
suggests that altering the mycobiome may aid in preventing or ameliorating disease. The
question yet remains whether or not disease causes changes in the mycobiome or vice
versa. As the field advances, mycobiome composition and alterations may be a predictor
of disease and more research will continue to define the association between fungi and
disease.

Table 1.3 Changes in the gut mycobiota associated with disease.
Disease status

Sample type and size

Methodology

Primers

Type 1 diabetes

Feces, n=35

Culture

n/a

Inflammatory
bowel disease

Colonic biopsies,
Crohn’s disease n=31
Ulcerative colitis n=26

18s rDNA, DGGE,
cloning, Sanger
sequencing

NS0/EF3
NS1/FR1
BF2/TR1

Crohn’s disease

Ileal mucosa & feces,
n=19

18s rRNA, DGGE,
cloning, Sanger
sequencing

NS1/FR1,
EF390/GC-FR-1

Familial
Crohn’s disease

Feces & mouth swabs,
n= 129 CD patients
n=113 healthy
relatives

Culture, biochemical tests,
latex agglutination

n/a

Preterm infants
(<32 weeks)

Feces, n=32,
(7 NEC, 13 sepsis)

28s rDNA, DGGE,
cloning, Sanger
sequencing

U1/U2-GC

Intestinal
transplant

Ileal effluent & feces,
n=2

Hepatitis B

Feces, cirrhosis n=38,
chronic hepatitis B
n=35

18s rDNA, DGGE,
cloning, Sanger
sequencing
Culture
18s, cloning, RFLP,
Sanger sequencing

NS1/FR1
EF390/GC-FR1
Unspecified

Findings
C. albicans identified in 40% of
subjects; significant difference
from 35 controls
Higher mean fungal diversity in
patients with CD; significant
difference from 47 controls
Fungal richness and diversity
significantly increased in patients,
C. albicans & C. tropicalis
abundant in patients and absent in 7
controls
C. albicans significantly more
frequent in CD patients and their
healthy relatives than from 14
control families
Fungal colonization in half of
infants; No fungal species were
observed in infants who developed
necrotizing enterocolitis
High fungal diversity soon after
transplant; less diversity >16-20
weeks post-transplant
Diversity of enteric fungi positively
correlated with disease progression

Reference
[192]

[152]

[113]

[193]

[195]

[112]

[30]
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Table 1.3 Continued.
Disease status

Sample type and size

Methodology

Primers

Findings

Hematologic
malignancy or
disorder

Feces, n=80

Culture, germ tube test,
biochemical test

n/a

Non-albicans Candida spp.
significantly higher in patients, C.
glabrata more prevalent in patients
than 61 controls

[6]

Hospital
inpatients

Feces, n=34

Culture, germ tube test,
biochemical test

n/a

Inpatients higher prevalence of
yeast, C. glabrata more prevalent in
inpatients

[97]

Extremely low
birth weight
infants

Feces, n=11

ITS, 454 pyrosequencing,
metagenomic shotgun
sequencing

ITS3/ITS4

Diabetes

Feces,
type 1 n=27, type 2=17

Quantitative real-time PCR

18s, FAM
Candida probe

Graft-versushost disease

Feces & oral,
GVHD n=59
GI-GVHD n=37

Culture

n/a

Patients colonized with Candida
spp. had a significantly higher rate
of grade II-IV acute GVHD

[205]

Pouchitis

Biopsy & feces,
n=36

18s, DGGE

NS1/FR1-GC

Patients who develop pouchitis have
higher fungal diversity and lower
bacterial diversity

[101]

n/a

Smoking habits highly associated to
Candida colonization; also
associated with Candida-vaginitis

[92]

n/a

Significant fungal colonization >104
CFU/ml in patients with gastric
ulcers

[227]

Varying
symptoms &
complaints
Gastric ulcers

Feces, n=308

Gastric juice, n=293

Culture

Culture, biochemical test

Candida spp. and Clavispora sp.
dominated, Candida quercitrusa
most abundant
Candida spp. significantly greater
in type 1 & type 2 patients than 17
controls

Reference

[108]

[65]
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1.9 DIET AND THE GASTROINTESTINAL MYCOBIOME
Diet is an environmental factor that influences the structure and diversity of
microorganisms in the gut [42]. Resident bacterial populations are associated with diet
and long-term dietary patterns [42]. However, few studies have investigated the
relationship between diet and the human intestinal mycobiome. One recent human study
demonstrated that consumption of high amounts of carbohydrates was positively
associated with Candida spp. colonization, while a diet high in amino acids, fatty acids,
and protein was negatively associated with Candida spp. [80]. Fungal abundance in the
gastrointestinal tract was also strongly associated with the composition of short-term diet.
Animal-based diets significantly increase Penicillium spp. [42], while Ukhanova et al.
showed pistachio and almond consumption does not significantly increase gut fungal
OTUs [203].
Intestinal populations of microorganisms are suspected of contributing to obesity
by way of diet [111]. The role of gut fungi in obesity is unknown. Only one study has
addressed this, focusing on the fungal communities in the human gut of a single obese
person and detecting 18 fungal species [66]. Conversely, a study identifying the fungal
community of a single anorexic human reported a “restricted” diversity of 10 fungal
species [67]. However, this number is not unusual for healthy individuals on a
conventional diet [74].

1.10 THE INTESTINAL MYCOBIOTA AND THE HOST IMMUE SYSTEM
The GI tract is home to the majority of both the human body’s commensal
microorganisms and immune cells. Little is known about the interaction between
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commensal intestinal fungi and the host immune system. Several players of the immune
system have been reported to play a critical role in fungal recognition and host defense
against disseminated fungal infections. These include Dectin-1, IL-17, and IL-22 [88].
Dectin-1 is a C-type lectin that plays a role in the innate immune response by functioning
as a pattern-recognition receptor and recognizing beta-glucans found in the cell walls of
fungi. In mice, Dectin-1 is of critical importance to defend against pathogenic fungi such
as Pneumocystis carinii and C. albicans [172, 200]. Humans deficient in Dectin-1 suffer
recurrent mucocutaneous candidiasis infections [57]. Genetic polymorphisms of Dectin-1
have also been associated with increased severity of ulcerative colitis [87, 204].
The cytokines IL-17 and IL-22 have been implicated in mucosal and antifungal
immunity. Mice deficient in components of the IL-17 pathway show increased
susceptibility to oral candidiasis and skin infections [37, 93]. Furthermore, IL-22 serves
as a first-line of defense against candidiasis in mice because IL-22 deficient mice are
more susceptible to GI candidiasis [43]. Mucosal immune responses to fungi are different
across human body sites. A complete understanding of the interaction between
commensal fungi and the immune system has yet to be unveiled.

1.11 CROSS-KINGDOM INTERACTIONS; POST-ANTIBIOTIC INTESTINAL
COMMUNITY REASSEMBLY
Interactions among microorganisms within the GI tract have long been recognized
as important determinants of community function [178]. Inhabitants are unlikely act in
isolation in the gut and, therefore, live in complex associations with one another.
Residents of the gastrointestinal microbiota are constantly interacting with one another,
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competing for nutrients and space and producing compounds that directly inhibit growth
or kill potential competitors [114]. Microbes in the gut may also form mutualistic and/or
commensal interactions with one another cooperating via syntrophy - using metabolic
waste products of another organism as nutrients - and constructing interspecies antibioticresistant biofilms [166, 219]. Hoffman et al. has best described the correlations between
fungi-bacteria and fungi-archaea [80]. The fungal phyla, Ascomycota and Basidiomycota,
significantly correlate with bacterial lineages. Candida and Saccharomyces commonly
co-occur with bacterial taxa Faecalibacterium, Bacteroides, Lachnospiraceae, and
Ruminococcaceae and these fungal genera are also positively associated with the
archaeon Methanobrevibacter and negatively associated with the archaeon
Nitrososphaera. Further analysis showed that Candida was negatively associated with
Bacteroides.
Bacteria and fungi interact with one another within an ecosystem physically and
chemically [154]. These interactions influence overall survival, colonization, and
virulence. Perhaps the most important bacterial-fungal interaction led to the discovery of
penicillin [61]. Physical interactions between fungi and bacteria include forming mixed
biofilms with one another and the ability of bacteria to attach to fungal hyphae, inhibiting
filamentation and biofilm formation [2, 155]. Bacteria also produce antifungal molecules
that affect morphology and virulence of Candida [81]. Bacteria have the ability to modify
the environment by lowering the pH and preventing hyphae formation by C. albicans
[27].
Bacteria and fungi are known to inhabit, and interact with one another at, multiple
human body sites. The species composition of the two may become beneficial or
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detrimental to the human host. Within the gastrointestinal microbiota, colonization
resistance is a known interaction that prevents overgrowth by endogenous organisms. The
bacterial microbiota reduces C. albicans colonization by excluding and out-competing
Candida for adhesion sites and producing inhibitory molecules [96]. Controlling fungal
colonization, especially by opportunists, with the use of probiotic bacteria is appealing.
One study showed the probiotic bacteria, Lactobacillus acidophilus and Lactobacillus
casei, induce protection against systemic candidiasis in mice [209]. Short chain fatty
acids (butyric acid) produced by lactic acid bacteria also inhibit filamentation and may
prevent C. albicans from causing disease [146].

1.11.1 Post-antibiotic recolonization
The ecological balance in the human gastrointestinal tract is important and
modulated, in part, by intestinal bacteria preventing fungal colonization and overgrowth.
However, when broad-spectrum antibiotics are administered they have the potential to
wipe out the entire bacterial community in the GI tract, perturb the equilibrium and allow
the host to become susceptible to infections by normally benign, commensal fungi such
as C. albicans [175]. Antibiotics are, therefore, a major risk factor for candidemia in
hospitalized patients [149, 213, 223].
Conversely, post-antibiotic recolonization of the bacterial gut microbiota is
shaped and altered by the presence of Candida. In the stomach of microbiome-disturbed
mice, C. albicans prevents Lactobacillus regrowth after antibiotic treatment and promotes
colonization of Enterococcus [125]. Presence of C. albicans in the murine cecum after
antibiotic treatment promotes Bacteroidetes populations, Enterococcus faecalis
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persistence, and inhibits Lactobacillus johnsonii [126]. Another recent study
demonstrated that the exogenous addition of C. albicans during treatment with the
cefoperazone in mice led to yeast overgrowth and substantially altered reassembly of the
bacterial community after treatment [52]. The combination of antibiotics and fungal
microbiota has been shown to promote the development of allergic airway disease [145,
147].
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CHAPTER 2
CHARACTERIZATION OF THE HUMAN GUT MYCOBIOME: VEGETARIAN
DIET AS AN ILLUSTRATION
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2.1 ABSTRACT
The fungal inhabitants of the gastrointestinal tract have been previously
overlooked in human microbiome studies. Here we present a survey of the fungal
microbiota in 16 fecal samples from healthy humans with a vegetarian diet. Fungi were
identified using molecular cloning and 454/Roche amplicon pyrosequencing of ITS gene
tags; additionally, samples were queried with a Luminex xTAG analyte specific reagent
(ASR) assay for fungal pathogens. Two fungal phyla were detected, with Ascomycota
present in all samples and Basidiomycota present in 81% of samples. Both sequencing
methodologies detected fungi in each fecal sample and in combination identified at least
57 fungal OTUs. The number of OTUs in each sample ranged from 2-25. A total of 31
fungal genera were found overall; 14 genera were present in only one sample and four
genera were present in only two samples. Malassezia was the most abundant genus,
followed by Aspergillus and Fusarium. Other abundant genera included Penicillium,
Alternaria, and Candida. Commonly detected fungi such as Aspergillus and Penicillium,
as well as known dietary fungi Agaricus bisporus and Ophiocordyceps sinensis, are
presumed to be transient, allochthonous members due to their abundance in the
environment or dietary associations. We also detected 17 fungal species not previously
reported from the gut. It is apparent that a wide variety of fungi can be identified from the
human gastrointestinal tract.
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2.2 INTRODUCTION
Over the last few decades, the composition and role of the bacterial gut
microbiota in humans has been studied extensively. The bacterial microbiota play an
integral part in the digestion of food, colonization resistance to invading pathogens, and
development of the immune system [8, 14, 25]. Until recently, microbiome studies have
failed to include eukaryotes in total community analyses, and eukaryotic diversity and
function in the gut is poorly understood. However, fungi are consistently identified as the
dominant human gut eukaryotes [44]. Knowledge of fungi in the gut opens a novel area
of research, where the same questions once asked about the role of gut bacteria in health
and disease are now being directed at the fungal microbiota (“mycobiota”).
Fungi are ubiquitous in the environment, and it is not surprising that humans have
co-evolved with fungi on many surfaces of the body [27]. Fungi are successful
commensals and pathogens of humans, despite the relative paucity of specialized
mammalian fungal pathogens [39]. Yeasts were first recognized to inhabit the
gastrointestinal (GI) tract in the early 1800s [5, 30]. However, only recently have we
started to appreciate and question their role. Cultivation studies show fungi to be
detectable in all sections of the GI tract of 70% of healthy adults, while the abundance –
106 fungal cells per gram of feces – is orders of magnitude smaller than that of gut
bacteria [4, 48, 49]. Alterations of the gut mycobiome have been associated with hepatitis
B and inflammatory bowel disease and increased fungal colonization has been shown to
impair mucosal barrier defense allowing translocation of gram-negative bacteria [7, 11,
41]. Mycobiome research also represents an important field of study due to the increasing
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number of invasive fungal infections in immunocompromised populations such as AIDS,
cancer, and organ transplant patients [35].
Culture-dependent methods used to characterize the intestinal mycobiome are
unable to optimally cultivate organisms of low abundance or those that require microbe–
microbe interactions [3]; additionally, many gut microbes require a modified atmosphere
for optimal growth. Thus, culture-independent methods, such as PCR-based cloning and
high-throughput DNA sequencing of fungal rRNA and ITS genes have become the
preferred method for mycobiome studies [12, 47]. No method has been unanimously used
and difficulties in defining the complete mycobiome are attributed to low sample
numbers, individual variation, limited attention, and a lack of consistent identification
methods and gene targets. In addition, several recent intestinal fungi investigations
described the diversity of the mycobiome based on a single fecal sample [18, 19, 22].
Factors such as diet, genetics, and environment play an influential role in
composition of the gut microbiota and help explain why differences in microbial
communities exist between human hosts [36]. Few studies have attempted to explore the
association between enteric fungi and diet [9, 23]. One previous study examining the
association between diet and intestinal fungi showed fungal abundance of Candida spp.
were positively correlated with recent consumption of a high carbohydrate diet, while
Candida spp. were negatively associated with diets high in amino acids, fatty acids, and
protein [23]. In an effort to deepen the understanding of dietary factors, we investigated
the intestinal mycobiome of healthy adults with a vegetarian diet.
It is evident that the present view of the intestinal mycobiome is incomplete. In
this study, we used molecular cloning and high-throughput ITS gene pyrosequencing to
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obtain a comprehensive survey of the human gastrointestinal mycobiome. We
additionally used a commercially available assay using multiplex-PCR with labeled
primers and subsequent sample hybridization to fluorescent microspheres (Luminex
xTAG analyte specific reagents [ASRs], Luminex Corporation, Austin, TX). This assay
was developed to target clinically relevant fungi [2], which include species of Candida
and Aspergillus that may be detected in the gut. Here we provide preliminary
characterization of the fungal communities in 16 fecal samples from the gastrointestinal
tract of healthy adult humans with a vegetarian diet. Furthermore, we compare three
culture-independent methods, and provide the first evaluation of Luminex fungal ASRs
on fecal DNA from healthy humans.

2.3 MATERIALS AND METHODS
Collection of fecal samples
The Institutional Review Board of the University of Nebraska approved all study
protocols (IRB Approval Number: 20111112037EP). Written informed consent was
obtained from all subjects to participate in this study. Fecal samples were obtained from
15 healthy human adults (6 male, 9 female; one male subject provided two fecal samples
two months apart, n=16). Study subjects were self-identified vegetarians (may or may not
eat eggs and/or dairy; no meat, fish or poultry consumption) and the participant ages
ranged from 19 to 48, with a mean of 23 and a median of 20. All participants were from
the Midwestern United States. After collection, each fecal sample was immediately
preserved at -80°C until the time of processing.
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DNA isolation
DNA was extracted using a modified method of the QIAamp® DNA stool mini
kit (QIAGEN) [38]. Briefly, feces were thawed on ice, and approximately 200 mg of
sample was diluted ten-fold in ice-cold phosphate buffered saline (PBS). Fecal
homogenates were transferred into a 2-ml sterile bead-beating tube containing 300 mg of
0.1-mm zirconium beads, and fungal cells were collected by centrifugation at room
temperature at 8,000 x g for 5 minutes. The cell pellets were washed three times with icecold PBS. The pellets were then resuspended in 100 μl lysis buffer (200 mM NaCl, 100
mM Tris pH 8.0, 20 mM EDTA) containing 20 mg/ml of lysing enzymes and incubated
at 37°C for 30 minutes. Using the kit reagents, 1.7 ml of Buffer ASL was added to each
tube and vortexed until the stool sample was thoroughly homogenized. Mechanical cell
lysis was performed by bead-beating each sample for two minutes at maximum speed
(MiniBeadbeater-8, BioSpec Products, USA). Isolation and purification of DNA from
fecal samples was continued following the manufacturer’s recommendations.

PCR amplification
PCR was performed using primers targeting the ITS1-5.8S-ITS2 region. Seminested PCR was used to detect fungal DNA amongst the predominant non-fungal DNA
present in fecal samples. The first round of amplification utilized the fungal-specific
ITS1-F forward primer [15] and the universal eukaryotic reverse primer TW13 [54] (see
Table 2.1 for primer sequences). Each PCR reaction mixture included 12.5 μl of REDTaq
ready mix (Sigma-Aldrich, St. Louis, MO), 2 μl (10 μM) of each oligonucleotide primer,
7.5 μl molecular biology-grade water, and 1 μl DNA template for a final volume of 25 μl.
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PCR reactions were performed on an Eppendorf Mastercycler and cycling conditions
were as follows: initial denaturation for 94°C for 4 min and 30 cycles at 94°C for 30 sec,
52°C for 1 min, 72°C for 1.5 min, followed by a final extension step of 72°C for 10 min.
After the initial reaction, a second reaction was performed using the primers ITS1-F and
ITS4 [54] and 1 μl of the template DNA from the first reaction. PCR amplicons were
separated using a 0.7% agarose gel in 1 x TAE buffer, stained with 0.5 μg/ml ethidium
bromide and visualized. PCR products were confirmed with bands around 500-600 bp.
Negative controls were used throughout the reactions to ensure contamination did not
occur.
Fusarium-specific PCR was performed with the following primer combinations:
GOFW and GORV, which specifically amplify a 435 bp fragment from the galactose
oxidase gene of F. graminearum [10] (see Table 2.1 for primer sequences); OPT18F470
and OPT18R470, which specifically amplify a 470 bp fragment from F. culmorum [46];
and 3CON, 3D3A, 3D15A, and 3NA, used in a multiplexing reaction to specifically
amplify 243, 610 and 840 fragments from the Tri3 gene in Fusarium producing 3acetyldeoxynivalenol, 15-acetyldeoxynivalenol, and nivalenol, respectively [50]. F.
graminearum PH-1 was included as a positive control, and 25 μl reactions followed the
protocols from the respective papers. Additionally, nested reactions were prepared using
the same primers and protocols as above, with 1 μl of the initial PCR reaction as
template, to account for the potentially low copy number in DNA extracted from fecal
samples.
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Table 2.1 PCR primers used in this study.
Primer

Sequence

Reference

ITS1-F

5’-CTTGGTCATTTAGAGGAAGTAA-3’

[15]

TW13

5’-GGTCCGTGTTTCAAGACG-3’

[54]

ITS4

5’-TCCTCCGCTTATTGATATGC-3’

[54]

GOFW

5’-ACCTCTGTTGTTCTTCCAGACGG-3’

[10]

GORV

5’-CTGGTCAGTATTAACCGTGTGTG-3’

[10]

OPT18F470

5’-GATGCCAGACCAAGACGAAG-3’

[46]

OPT18R470

5’-GATGCCAGACGCACTAAGAT-3’

[46]

3CON

5’-TGGCAAAGACTGGTTCAC-3’

[50]

3D3A

5’-CGCATTGGCTAACACATG-3’

[50]

3D15A

5’-ACTGACCCAAGCTGCCATC-3’

[50]

3NA

5’-GTGCACAGAATATACGAGC-3’

[50]

Molecular cloning
PCR products were purified using the Wizard Genomic DNA purification kit
(Promega, Madison, WI). Purified products were ligated into pGEM®-T Easy vectors and
transformed into JM109 High Efficiency Competent cells (Promega, Lyon, France)
following the manufacturer’s instructions. Subsequently, 10 colonies negative for βgalactosidase activity were chosen and sequenced by dideoxy (Sanger) sequencing at
Michigan State University’s Research Technology Support Facility (East Lansing, MI).
Samples were identified by sequence homology using nucleotide BLAST against the
UNITE curated fungal ITS sequence database [29] and the curated FUNCBS database, as
accessed through the Centraalbureau voor Schimmelcultures
(www.cbs.knaw.nl/Collections/BioloMICSSequences.aspx?file=all; accessed July 2014).
Sequences have been deposited in GenBank as accession # KP196567-KP196602.
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Pyrosequencing of the fungal ITS genes
Extracted DNA from fecal samples was selectively amplified by PCR using
primers targeting the ITS1-5.8S-ITS2 genes. PCR reaction mixtures consisted of 25 μl
REDTaq ready mix (Sigma-Aldrich, St. Louis, MO), 4 μl ITS1-F (10 pmol), 4 μl TW13
(10 pmol), 15 μl molecular biology-grade water, and 2 μl DNA template. PCR was
performed on an Eppendorf Mastercycler using the following conditions: 95°C for 15
min and 30 cycles of 94°C for 30 sec, 52°C for 30 sec and 72°C for 1 min, followed by a
final elongation for 72°C for 10 min. PCR products were purified using the Wizard SV
Gel and PCR Clean-up Kit (Promega, Madison, WI). Following cleanup, amplicon
products from all samples were mixed in equal concentrations and purified using
Agencourt Ampure beads (Agencourt Bioscience Corp., MA, USA). Samples were
sequenced at MR DNA (Shallowater, TX) using tag-encoded FLX amplicon
pyrosequencing on 454/Roche GS FLX Sequencer technology [13, 51]. Data processing
and analysis followed Hume and colleagues [26]. Rarefaction analysis based on observed
OTU metrics was performed to assess community coverage using QIIME (v. 1.8.0) [6]
with default settings. Alpha diversity of the samples was measured based on Simpson and
Shannon’s coefficients in QIIME [6]. One sample with null diversity (only one OTU
detected) was removed from analysis. Raw sequences have been deposited in GenBank
under BioProject PRNJA268649.

Luminex Fungal xTAG ASR Assay
A multiplex xTAG fungal analyte-specific reagent (ASR) assay consisting of 23
ASRs developed by Luminex Molecular Diagnostics was used for the simultaneous
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detection and identification of multiple fungal pathogens in the fecal samples. The
following ASRs were used: xTAG Aspergillus flavus, xTAG Aspergillus fumigatus,
xTAG Aspergillus niger, xTAG Aspergillus terreus, xTAG Blastomyces dermatitidis,
xTAG Candida albicans, xTAG Candida glabrata, xTAG Candida guilliermondii,
xTAG Candida krusei, xTAG Candida lusitaniae, xTAG Candida parapsilosis, xTAG
Candida tropicalis, xTAG Coccidioides immitis, xTAG Cryptococcus neoformans,
xTAG Fusarium, xTAG Histoplasma capsulatum, xTAG Mucor indicus, xTAG
Pneumocystis jirovecii, xTAG Rhizopus microsporus, xTAG Rhizopus arrhizus, xTAG
Scedosporium apiospermum, xTAG Scedosporium prolificans, and xTAG Tremella.
Multiplex PCR, bead hybridization, and detection were performed on DNA extracted
from fecal samples above following the protocol of Babady and colleagues [2]. The
samples were analyzed on the Luminex MAGPIX system (Luminex Corp., Austin, TX)
and median fluorescence intensity (MFI) values were calculated by the xPONENT 4.2
software. A threshold value of 225 MFI was set for positive targets, values below 200
MFI were negative, and 200-224 MFI were equivocal.

2.4 RESULTS
Sequencing methods
The gut mycobiota of 16 fecal samples from humans with a vegetarian diet was
characterized using molecular cloning and 454/Roche amplicon pyrosequencing. Each
method was able to identify fungi in the samples provided after amplification of the
fungal ITS genes. The gut mycobiota was first identified using a traditional Sanger
sequencing-based method via molecular cloning and secondly by 454/Roche
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pyrosequencing of the ITS1-ITS2 genes. After removing singletons from pyrosequencing
data, which account for a major source of biases [52], the total number of sequences
obtained from 16 samples was 186,495 (mean 11,656; median 7,802). The predominant
fungal taxa identified differed for the two methods. Molecular cloning identified
Aspergillus as the most abundant genus and 454 pyrosequencing identified Fusarium,
Malassezia, and Penicillium as the most abundant genera. Pyrosequencing identified 41
fungal operational taxonomic units (OTUs) that cloning failed to detect. In contrast,
Leptosphaerulina chartarum was only detected by molecular cloning.

Identification of fungi in fecal samples
Combining both sequencing methods, two fungal phyla were observed in the
samples: Ascomycota and Basidiomycota. Ascomycetes were present in all 16 samples
and basidiomycetes were found in 13 samples. A total of 31 fungal genera were detected
(mean 7; median 7; range 2-14 per sample). Fourteen genera were present in only one
sample and four genera were present in only two samples. Malassezia was the most
commonly detected genus, in 81% of samples (Figure 2.1). Aspergillus and Fusarium
were the second most commonly detected genera, present in 75% of samples, followed
by Penicillium (69%), Alternaria (56%), and Candida (50%). Other fungal genera found
in 25% or more of samples included Agaricus, Cladosporium, and Debaryomyces.
At the lowest discernible taxonomic level, pyrosequencing and molecular cloning
identified at least 57 fungal operational taxonomic units (OTUs). The number of OTUs in
an individual sample ranged from 2-25 (mean 12; median 10.5). Twenty-seven fungal
OTUs were present in only one sample and 6 OTUs were present in only two samples.
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The most abundant OTUs included: Malassezia restricta (81%), Fusarium cf.
graminearum (75%), Aspergillus cf. niger (69%), Penicillium cf. roqueforti (69%),
Penicillium cf. commune (63%), Alternaria spp. (56%), and Debaryomyces hansenii
(44%). Other ascomycetes identified included Aspergillus cf. oryzae, Candida albicans,
Candida tropicalis, Galactomyces sp., Ophiocordyceps sinensis, and Saccharomyces
cerevisiae. Across all the samples analyzed, no species were common to all individuals.
The overall distribution of fungi in 16 fecal samples obtained from healthy human
vegetarians by 454 pyrosequencing is shown in Figure 2.2. Alpha diversity of the fungal
fecal community was measured with Shannon’s (1.70 +/- 0.86) and Simpson’s (0.53 +/0.25) indices (Figure 2.3). Both indices revealed substantial variation in community
diversity within individuals, as in some subjects only one fungal OTU was detected (null
diversity), whereas in others up to 24 distinct OTUs were detected by pyrosequencing.
Rarefaction analysis revealed that for the majority of samples community coverage
reached saturation (Figure 2.4). For 75% of the samples, 600 sequences per sample
covered the fungal diversity of the gastrointestinal tract in humans.
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Figure 2.1 Detection frequency of fungal genera in 16 fecal samples using molecular
cloning and 454 pyrosequencing. Only genera present in greater than ten percent of
samples are shown. Phylum affiliation for each genus is indicated: Ascomycota (orange),
Basidiomycota (blue).

Figure 2.2 Overall distribution of gut fungi. Fungi in more than fifteen percent of fecal
samples from healthy individuals with a vegetarian diet obtained by 454 pyrosequencing
are shown.
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Figure 2.3 Alpha diversity of the fungal fecal community. A) Shannon’s diversity
index, and B) Simpson’s diversity index.
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Figure 2.4 Rarefaction analysis of ITS pyrosequencing tags in fecal samples from
adults with a vegetarian diet, showing saturation at approximately 600 sequences.

Fusarium PCR
One or more Fusarium species affiliated with F. graminearum was detected in
many samples. Our lab does ongoing research with Fusarium graminearum Michigan
field isolate PH-1 (FGSC 9075, NRRL 31084). To determine whether the Fusarium
detected in the samples was due to lab contamination, several Fusarium-specific PCR
reactions were performed. Galactose oxidase PCR amplifies a 435 bp fragment of F.
graminearum while not amplifying related species [10], while the randomly-selected
OPT18 primers specifically amplify a 470 bp fragment from F. culmorum [46]. Only one
of the study samples yielded PCR results consistent with strain PH-1, though multiple
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bands of other sizes amplified (Figure 2.5), suggesting 1) the presence of Fusarium other
than F. graminearum; 2) that the high level of Fusarium detected by all detection
methods was not due to contamination with the lab organism; and 3) amplification of
non-Fusarium species (also present in the DNA) by the PCR primers.

Fungal xTAG ASR Assay
A commercially available fungal ASR panel allows for the detection of 23 species
of fungi: 22 human pathogens and Tremella, which is included as an internal control. Six
of the fungi detected by the sequencing methods have ASRs available: Aspergillus flavus,
A. fumigatus, A. niger, Candida albicans, C. tropicalis, and Fusarium. The ASR assay
detected Fusarium in 10 samples, C. albicans in three, and C. tropicalis in two (Table
2.2). Despite Aspergillus species being detected in 10 samples by pyrosequencing and
cloning, the ASR assay only detected A. flavus (= A. oryzae) in a single sample. While we
performed all 23 ASRs on all samples, the ASR assay did not detect any species that had
not also been detected by sequencing.
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Figure 2.5 A) Galactose oxidase and B) Tri3 PCR products from DNA samples
identified as containing Fusarium. 1KB+: 1 KB Plus ladder (Invitrogen), PH1:
Fusarium graminearum strain PH-1 (NRRL 31084). The galactose oxidase primers yield
a product of 435 bp for Fusarium graminearum, present in PH1 and study samples M5
and (possibly) F3. The multiplexing Tri3 primers yield bands of 243, 610 and 840 bp for
3-acetyldeoxynivalenol, 15-acetyldeoxynivalenol, and nivalenol, chemotypes,
respectively. A band of the appropriate size for 15-acetyldeoxynivalenol is present in
PH1, M5 and F3; other bands are visible, but do not correspond with validated
trichothecene mycotoxin chemotypes. Clear differences are visible between PH1 and
study samples.

Table 2.2 Fungi detected in fecal samples from healthy adult vegetarians, by 454 pyrosequencing, cloning, and Luminex ASR
assays.
OTU

M1

M2

M3a

M3b

M4

M5

M6

F1

F2

F3

F4

F5

F6

F7

F8

F9

Agaricus bisporus

3781

0

438

12

0

15

0

0

0

0

0

0

0

0

0

0

Alternaria spp.

704

0

12800

1413

54

1008

0

34497

0

7761

0

0

0

5

0

2433

Ascocoryne cylichnium

0

0

0

0

0

0

0

0

1340

0

0

0

0

0

0

0

Ascocoryne sarcoides

0

0

0

0

0

0

0

0

2

0

0

0

0

0

0

0

Ascomycota sp.

4

2

0

0

0

0

0

0

3

0

0

0

0

0

0

0

Aspergillus fumigatus

0

548

0

0

74

0

0

0

396

0

0

0

0

0

0

0

Aspergillus cf. niger

0

0

506

33

0

10862

0

0

0

39

5290

0

0

0

10226

0

Aspergillus cf. oryzae

0

0

0

0

0

0

0

0

0

590

211

0

0

1373

0

0

Aspergillus spp.

0

8

4

0

0

74

0

0

0

0

29

0

0

0

240

0

Candida albicans

2

2197

0

5

0

0

0

0

0

0

0

0

18933

0

371

0

Candida sp.

0

0

0

4

0

0

0

0

0

0

0

0

0

0

0

0

Candida tropicalis

562

0

0

292

0

0

5

0

0

0

284

181

2

0

0

0

Capnodiales sp.

0

0

0

18

0

0

0

0

0

37

0

0

0

0

0

0

Cladosporium spp.

0

0

0

436

0

0

0

0

0

802

0

0

184

0

0

0

Cryptococcus amylolyticus

0

0

0

1336

0

0

0

0

0

0

0

0

0

0

0

0

Cryptococcus tephrensis

0

0

0

0

0

0

0

0

0

1551

0

0

0

0

0

0

Cyberlindnera jadinii

0

14

0

0

0

0

0

279

0

6

0

0

0

0

0

0

Debaryomyces hansenii

0

196

0

111

0

0

0

0

0

0

0

0

37

0

2
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Diplodia mutila

0

0

0

0

0

295

0

0

0

0

0

0

0

0

0

0
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Table 2.2 Continued.
OTU

M1

M2

M3a

M3b

M4

M5

M6

F1

F2

F3

F4

F5

F6

F7

F8

F9

Epicoccum nigrum

0

0

0

216

0

0

0

0

0

0

0

0

0

0

0

0

Eurotium niveoglaucum

0

0

0

0

0

0

0

0

2

0

0

0

0

0

0

0

Eurotium rubrum

0

0

0

0

0

0

0

0

2475

0

0

0

0

0

0

0

Eurotium sp.

0

0

0

0

0

0

0

0

0

0

890

0

0

0

257

0

Exophiala heteromorpha

0

0

0

246

0

0

0

0

0

0

0

0

0

0

0

0

Fusarium cf. graminearum

47

264

0

170

455

710

0

0

890

0

868

883

1026

2513

18

0

Galactomyces sp.

0

0

2208

0

0

0

0

0

0

0

0

0

0

0

0

0

Lecythophora spp.

576

0

0

0

250

0

0

0

0

0

0

0

0

0

0

0

Leptosphaerulina chartarum

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Malassezia globosa

0

0

0

0

11

0

0

0

0

0

0

0

0

0

0

0

Malassezia pachydermatis

0

0

0

0

0

14

0

0

0

0

0

0

0

0

0

0

Malassezia restricta

13

179

0

0

8

73

0

671

120

422

30

0

195

2

0

0

Malassezia slooffiae

0

0

0

171

0

0

0

0

0

0

0

0

0

0

0

0

Malassezia sp.

5

89

0

0

11

10

0

0

73

345

0

0

0

5

0

0

Malassezia sympodialis

0

0

0

0

0

450

0

0

0

0

0

0

0

0

0

0

Mrakia sp.

0

0

0

0

0

0

0

0

0

3

0

0

0

0

0

0

Mycosphaerellaceae sp.

0

0

0

2

0

0

0

0

0

4

0

0

0

0

0

0

Neosartorya fischeri

0

4

0

0

6

0

0

0

3

0

0

0

0

0

0

0

Ophiocordyceps sinensis

0

0

0

0

0

0

0

0

120

0

40

0

0

0

0

0

Penicillium cf. commune

582

22

0

187

210

0

0

627

4

1398

9

60

4

0

0

0
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Table 2.2 Continued.
OTU

M1

M2

M3a

M3b

M4

M5

M6

F1

F2

F3

F4

F5

F6

F7

F8

F9

Penicillium cf. roqueforti

136

445

0

75

74

0

0

56

802

656

42

39

161

0

0

64

Penicillium spp.

12

0

0

4

7

0

0

628

2

34

14

0

2

0

0

0

Penicillium turbatum

0

0

0

0

0

0

0

6

0

0

0

0

0

0

0

0

Phialocephala lagerbergii

0

0

0

6

0

0

0

0

0

0

0

0

0

0

0

0

Pholiota sp.

0

0

0

0

0

0

0

0

0

0

36

0

0

0

0

0

Pichia kudriavzevii

0

0

0

0

0

0

0

22692

0

0

0

0

0

0

0

0

Pleosporales sp.

6

0

0

9

0

0

0

0

4

73

0

0

0

0

0

3

Rhodotorula sp.

332

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Saccharomycetales sp.

0

1729

0

8

0

0

0

0

0

0

0

0

0

0

119

2

Saccharomyces cerevisiae

3

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Sphaerotheca fusca

0

0

0

0

0

0

0

0

0

0

0

0

2

0

0

0

Torulaspora sp.

0

0

0

13

0

0

0

0

0

0

0

0

0

0

0

0

Trichocomaceae spp.

0

0

0

0

0

0

0

0

18

5

0

0

0

0

0

0

Trichoderma longibrachiatum

0

0

0

0

0

0

0

0

0

0

20

0

0

0

0

0

Unclassified "Fungus A"

10

0

0

24

0

0

0

0

0

89

0

0

0

0

0

27

Unclassified "Fungus C"

134

1558

0

308

510

0

0

0

1590

2015

0

1161

0

4438

4

84

Unclassified "Fungus D"

61

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Wallemia muriae

0

0

0

0

0

7

0

0

0

0

0

0

0

0

0

0

6970

7255

15956

5099

1670

13518

5

59456

7844

15830

7763

2324

20546

8336

11237

2683

Sum from 454

Numbers = number of 454 sequences. Clones are indicated by a box around the corresponding cell. ASR data is color-coded: green for
present, red for absent, and yellow for equivocal.
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Temporal analysis of fungal diversity
The subject who provided fecal samples at two different time points showed little
similarity and stability over time (Figure 2.2; M3a & M3b). The fecal sample from the
first time point yielded 15,959 hits from five OTUs and the second fecal sample yielded
5,099 hits from 24 OTUs. Only three OTUs were common between both time points
(Agaricus bisporus, Alternaria spp., and Aspergillus cf. niger). Four genera were detected
in the first time point and 14 genera were detected in the second time point.

2.5 DISCUSSION
The gut mycobiome of adult vegetarians
We have demonstrated that the composition of the human gut microbiome is
diverse among healthy adult humans with a vegetarian diet, identifying a total of at least
57 different OTUs from two fungal phyla, with a mean of approximately 12 OTUs per
subject. On average, the vegetarian gut mycobiome does not appear diminished in
diversity compared to the mycobiome of healthy individuals on a conventional diet and is
more diverse compared to the mycobiome of an individual with anorexia nervosa [18,
23]. This study shows that the detectable fungal diversity is not limited to only a few
fungal genera or species; however, it may be argued that use of the term “mycobiome”
for all of these species is misleading, as a majority are allochthonous. In addition, we
have also discovered fungal species previously undescribed in the human gut (Table 2.3).
Here we report the most commonly detected gut fungus among vegetarians to be
M. restricta. Other gut fungi studies detect M. restricta and Malassezia species in the gut
[19, 22]. There is considerable variation among human gut fungal culture-independent
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studies regarding which fungal species is the most dominant. Gloeotinia/Paecilomyces,
Galactomyces, Candida, Saccharomyces, and Penicillium have all been documented as
the most abundant fungi in the GI tract of the studied cohort [7, 23, 33, 41, 45].
Abundance discrepancies among studies may be due to differences in in the individuals’
diet, environment, host genetics, age, gender, ethnicity, health status or ultimately the
chosen methodology for detection.

Table 2.3 Unique fungal species from the gastrointestinal tract of vegetarians not previously detected in human gut
mycobiome studies.
Phylum
Ascomycota

Class
Pezizomycotina

Order

Ecological Niche

Botryosphaeriales

Diplodia mutila

Causes tree branch cankers; pathogen of apples, pears, grapes

Chaetothyriales

Exophiala heteromorpha

Environmental fungus; causes phaeohyphomycosis infections

Erysiphales

Sphaerotheca fusca

Powdery mildew fungus

Eurotiales

Eurotium niveoglaucum

Widespread environmental osmophile

Penicillium turbatum

Rotten wood

Ascocoryne cylichnium

Saprobic fungus of hardwoods and conifers

Ascocoryne sarcoides

Saprobic jelly fungus

Phialocephala lagerbergii

Wood-inhabiting fungus

Ophiocordyceps sinensis

Caterpillar fungus; used as herbal supplement

Trichoderma longibrachiatum

Common house mold; causes allergic fungal sinusitis

Epicoccum nigrum

Common in environment; plant pathogen cereals and nuts, spoilage

Leptosphaerulina chartarum

Leaf blight; high-level xylanolytic enzyme production

Sordariales

Lecythophora sp.

Dematiaceous mold; isolated from soil and from plant debris

Saccharomycotina

Saccharomycetales

Pichia kudriavzevii

Spoilage yeast; found in soil, fruits; surface biofilms

Agaricomycotina

Agaricales

Pholiota sp.

Wood-rotting saprobic mushroom

Tremellales

Cryptococcus amylolyticus

Soil organism

Malasseziales

Malassezia slooffiae

Human skin commensal-external ear canal; dermatitis in goats

Helotiales

Hypocreales

Pleosporales

Basidiomycota

Taxa

Ustilaginomycotina
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A previous study in our lab, employing the same DNA extraction, amplification,
and 454 pyrosequencing methods on fecal samples from adults approximately from the
same geographical location (upper Midwest) on a conventional diet, identified C.
tropicalis as the most abundant gut fungus, present in 57% of 69 samples, followed by
Galactomyces in 49%. [21]. Malassezia, Aspergillus, Fusarium, and Penicillium species
were identified, but from a much smaller proportion of samples than in this study;
conversely, only one vegetarian sample contained Galactomyces. Candida tropicalis was
detected in 25% of the vegetarian samples, and the genus Candida in 50%.
The relationship between diet and the gut mycobiome remains poorly understood.
Bacterial microbiome studies have shown that the microbiota of an individual with a
vegetarian diet is substantially different and shifted in composition in comparison with a
conventional diet [28, 55]. This suggests that fungal abundance may also be a reflection
of diet and shifts towards certain populations may occur depending on the chosen dietary
habits of the individual. Further research is necessary to determine how diet can induce
significant compositional changes in the gut microbiota.

Identification of fungi using ITS
The internal transcribed spacers between the nuclear ribosomal RNA genes have
rightly been selected as fungal barcoding sequences, due to their ease of amplification,
multicopy nature, and extreme sequence divergence allowing for species-level
identification in a majority of cases [47]. However, fungal identification is only as good
as the available databases, and not all species have been sequenced. Additionally, some
species are so closely related that ITS cannot accurately distinguish between them. In this
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study, indistinguishable species include Alternaria alternata/A. arborescens/A.
brassicicola/A. citri/A. mali/A. tenuissima, Aspergillus flavus/A. oryzae, Aspergillus
niger/A. carbonarius/A. foetidus/A. tubingensis, Cladosporium cladosporioides/C.
bruhnei/C. colocasiae/C. herbarum/C. macrocarpum/C. oxysporum/C.
pseudocladosporioides/C. sphaerospermum/C. tenuissimum, Fusarium graminearum/F.
culmorum/F. asiaticum; Penicillium camemberti/P. allii/P. aurantiogriseum/P.
chrysogenum/P. commune/P. dipodomyicola/P. freii/P. glandicola/P. italicum/P. solitum,
and P. roqueforti/P. carneum/P. paneum. We refer to these as Aspergillus cf. niger,
Fusarium cf. graminearum, etc.; it should be understood that these are not precise species
identifications.

OTUs of interest
Among the ascomycetes, members of the genus Aspergillus were commonly
detected among the samples. Aspergillus species play important roles in industry, the
environment, and human health. Aspergillus cf. oryzae, found in three samples,
encompasses A. oryzae, used in soy fermentations, and its wild progenitor, the toxigenic
A. flavus. Aspergillus fumigatus, detected in three samples, is one of the most ubiquitous
airborne fungi, and humans will inhale hundreds of Aspergillus conidia per day [17, 24].
Consequently, A. fumigatus has become the leading cause of aspergillosis and causes
fatal invasive infections, resulting in death in 50% of all cases [32]. In addition, our study
showed 11 samples of Aspergillus cf. niger. A. niger and related species are capable of
causing human pulmonary infections and contaminating a wide range of food
commodities [39, 42, 43].
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Penicillium species were also commonly detected in the GI tract of our study
cohort. Penicillium is a large, diverse genus of fungi capable of growing in almost any
environment [43]. Penicillium species are among the main causes of food spoilage
because of their psychotropic characteristic, allowing them to tolerate refrigeration
temperatures. Many Penicillium species detected in this study might be a result of
consuming contaminated foods. In addition, P. camemberti and P. roqueforti are widely
used in the production of mold-ripened cheeses.
The frequency of Candida species detected in this study was 50%. Candida
species, including C. albicans and C. tropicalis, are commensals of the gastrointestinal,
reproductive, and respiratory tracts and skin. Candida species are of substantial clinical
significance because of their ability to become opportunistic pathogens responsible for a
spectrum of diseases, ranging from mucosal, cutaneous, invasive infections when host
resistance is decreased [27]. Candida species are considered to be the most widely
distributed and dominant fungi in the human gut mycobiome. In healthy individuals,
carriage of Candida albicans is estimated to be 30-60% [40].
Five species of Malassezia were identified from the gut of our cohort: M. globosa,
M. pachydermatis, M. restricta, M. slooffiae, and M. sympodialis. Malassezia species are
lipophilic yeasts found naturally on the skin and are associated with a number of skin
diseases and dandruff [20]. Malassezia has been commonly detected in fecal samples [7,
18, 22, 33], however, here we report for the first time detection of M. slooffiae. The
detection of Malassezia species across gut mycobiome studies may suggest a role for its
presence in the gut due to the favorable lipid-rich environment provided by the host’s
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diet. Thus, more research is needed to determine if Malassezia species are true gut
commensals or merely contaminants.
The introduction of unequivocal food-associated fungi, including dietary
mushrooms, is not uncommon in the human distal gut [9, 12]. The basidiomycete,
Agaricus bisporus (white button mushroom, portabello, crimini) was detected in four
subjects. A. bisporus is the most commonly cultivated edible mushroom worldwide [31]
and the most widely consumed mushroom in Western countries; its detection in feces is
almost certainly due to consumption. The yeasts Saccharomyces cerevisiae and
Debaryomyces hansenii, are used in the production of fermented foods. Ophiocordyceps,
detected in two individuals, is used as a dietary herbal supplement for a variety of
therapeutic practices.
Other fungi detected in this study, such as Epicoccum nigrum, Diplodia mutila,
Alternaria spp., Podosphaera xanthii, and Fusarium cf. graminearum, are known plant
pathogens. These fungi may be present in the intestinal tract due to the consumption of
contaminated foods or consumables requiring the use of fungi for production. Fungi for
which this study provides the first report in the human gut are shown in Table 2.3,
together with probable sources.

Transient nature of intestinal fungi
Our results demonstrate that many fungi present in the gut are of allochthonous
origin due to their known presence in the environment or foodstuffs. We cannot conclude
that all of the fungi reported in this study are autochthonous organisms and will remain in
the gut over time; indeed, the ecology (when known) of the organisms (Table 2.3)
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suggests a plausible environmental source for most, while several grow poorly if at all at
human body temperatures. Bacterial gut microbiome studies show bacteria to be
temporally stable over time [36, 53]. One study documented the transient nature of
foodborne fungal microbes in the distal gut by sequencing the ITS genes from food and
fecal samples [9]. A previous study of the micro-eukaryotic diversity in the gut
demonstrated a temporally stable fungal gut community using a fungal internal
transcribed spacer-based analysis [45]; conversely, Hallen-Adams et al. [21] observed
high variability and low persistence of gut fungi from 24 individuals’ samples at two time
points. The subject in the current study who was sampled at two different time points
showed little similarity over time. The paucity of data from multiple study subjects limits
the ability to draw broad conclusions of fungal stability in the gut over time.

Comparison of methods
Fungi are increasingly being recognized as an important component of the gut
microbiota. Over the last two decades, cloning and Sanger sequencing have been the
foundation for microbial sequencing [16]. 454 pyrosequencing represents a method for
rapidly characterizing microbial communities in a high-throughput, efficient, relatively
rapid and cost-effective manner [37]. In the current study, we used a combination of two
different sequencing methods to identify the fungal composition in the gut of humans
with a vegetarian diet. In some instances one method and not the other detected fungal
sequences. 454 pyrosequencing identified 41 OTUs that cloning failed to detect. That
pyrosequencing should detect more OTUs than cloning was not unanticipated;
pyrosequencing generated several thousands of sequences per sample, while 10 clones
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from each cloning reaction were selected for further analysis, and only those with distinct
restriction patterns were sequenced. Tedersoo et al. [52] reported that by combining
Sanger sequencing and 454 pyrosequencing they were able to identify 141 species of
ectomycorrhizal fungi in root samples. Approximately 66% of them were common
between the two methodologies, and they concluded considerable methodology biases
towards certain lineages existed. These two methods, especially when used in
conjunction with one another, represent potentially useful methods to characterize the
mycobiome due to the low abundance and diversity of gut fungi.
Of more interest is the correlation between the two methods; 55% of the OTUs
identified by cloning were the same OTUs identified by pyrosequencing, and in 25% of
the samples, the OTUs pyrosequencing identified as highest abundance (Figure 2.2, Table
2.2) were present in the clone sequences. Several species detected by cloning were not
among the tops hits identified by pyrosequencing in their respective sample. For example,
cloning was able to identify Cyberlindnera jadinii in a sample that only had six
pyrosequencing hits. Cloning was able to identify six OTUs that had less than 20 hits in
pyrosequencing, while 16 OTUs identified by cloning never appeared in the
pyrosequencing data of that sample.
Of the six taxa found in our samples for which ASRs were available, the ASRs
showed the highest detection of Fusarium (10 samples), which also represented the most
commonly detected OTU in the pyrosequencing (11 samples) data. In 3 samples
Fusarium was detected by all three methods; in 5 samples by ASRs and pyrosequencing;
in 3 samples by cloning and pyrosequencing; and in 1 sample by cloning alone. In 1
sample, C. albicans was detected by all three methods, in 2 samples by ASRs alone, and
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in 2 samples by pyrosequencing alone. The ASR assay detected C. tropicalis from 2 out
of 4 samples in which it was detected by pyrosequencing.
The Aspergillus fumigatus and A. niger ASRs failed to detect anything, despite
high representation of these OTUs in the sequencing data (3 samples with A. fumigatus
and 6 with A. cf. niger by pyrosequencing, and 10 samples with A. cf. niger clones). As
our A. cf. niger is imperfectly identified, it is possible that this ASR shows high fidelity
to A. niger sensu stricto, and is not detecting the OTU(s) in our samples. Babady and
colleagues [2], evaluating the ASR assay on clinical samples, report that certain isolates
they had identified as A. niger were not detected by the A. niger ASR and were
subsequently determined to be A. tubingensis; additionally, Babady and colleagues [2]
report suboptimal detection of A. fumigatus and A. flavus.
All methods discussed are limited by dependence on PCR during sample
preparation, the results of which are influenced by primer choice and template
characteristics as well as initial template abundance [52]. A serious limitation in
microbiome studies in general is the difficulty in obtaining reliable measures of OTU
abundance within sample, let alone making between-sample comparisons. It is tempting
to conclude that a higher number of 454 sequences or clones, or higher median
fluorescence in the case of ASRs, equates to greater abundance, but in truth the pool may
be influenced by PCR biases; the limitations of each technology; and the multicopy
nature of the nuclear ribosomal region, which differs substantially in copy number
between organisms (180 copies in the sequenced strain of Fusarium graminearum vs. 55
copies in Candida albicans; Liti and colleagues [34] report copy numbers ranging from
54-511 in different strains of Saccharomyces cerevisiae). Amend, Seifert and Bruns [1]
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report a tenfold difference in 454 read counts between species from samples prepared
with the same spore counts of each species, and conclude that while read abundance may
be quantitative within species, between-species comparisons are unreliable. We are not
confident that any method used in this study provides quantitative data; however, alone
and in combination, a snapshot of gut fungal diversity is produced.
In conclusion, the human gut mycobiome is diverse and dynamic. Many fungi are
allochthonous due to the high level of exposure to environment or food-associated fungi.
One must be cautious in drawing conclusions about the role of fungi, as a majority are
“passing through,” and their contribution to the gut ecology is likely to be minimal. The
different methodologies displayed differing strengths, weaknesses and biases: notably,
the ASR assay is limited to detecting species for which there are primers, cloning is
limited by the number of clones selected for sequencing, and all three methods are
subject to PCR biases. As gut mycologists continue to expand gut mycobiome studies we
will begin to understand their beneficial and/or detrimental roles in human health.
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CHAPTER 3
EPIDEMIOLOGICAL INVESTIGATION OF CANDIDA SPECIES CAUSING
BLOODSTREAM INFECTION IN PEDIATRIC SMALL BOWEL TRANSPLANT
RECIPIENTS
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3.1 ABSTRACT
Small bowel transplantation (SBT) is a life-saving medical procedure for patients
with short bowel syndrome; however, these patients remain at high risk for bloodstream
infections. Gastrointestinal carriage and exogenous acquisition of Candida are potential
sources of infection. This research aims to characterize the SBT recipient gut microbiota
over time following transplant and investigate the epidemiology of candidemia in seven
pediatric SBT recipients at the University of Nebraska Medical Center. Candida species
from the recipient ileum and bloodstream were identified by ITS sequence and identified
to strain by multilocus sequence typing and randomly amplified polymorphic DNA.
Twenty-one ileostomy samples harbored at least one Candida species (C. albicans, C.
glabrata, C. lusitaniae, C. parapsilosis, C. tropicalis). Bloodstream infections were
caused by C. parapsilosis (3), C. albicans (2), C. glabrata (1), C. orthopsilosis (1), and
Wickerhamomyces anomalus (1). Two transplant patients were confirmed to harbor the
same strain of Candida in the ileum and bloodstream while a third patient had distinct
ileal and bloodstream Candida strains. Results are congruent with at least two infections
arising from the recipient GI tract (C. albicans, C. glabrata) and one infection arising
from Candida other than that colonizing the recipient GI tract (C. parapsilosis). Results
also suggest two patients were infected by the same strain of C. parapsilosis. Antifungal
susceptibility testing revealed that all isolates, with the exception of three, showed
susceptibility to all the antifungals tested. One C. glabrata isolate showed multidrug
resistance to itraconazole, amphotericin B, and posaconazole and was classified as
susceptible dose-dependent to fluconazole and voriconazole.
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3.2 INTRODUCTION
Short bowel syndrome (SBS) is a fatal gastrointestinal disorder characterized by
the inability to absorb enough nutrients and fluids to sustain life [86]. The most common
cause of pediatric SBS is extensive loss of the small bowel due to congenital birth defects
(e.g. midgut volvulus, gastroschisis, intestinal atresia) or surgical removal to treat
intestinal diseases (e.g. necrotizing enterocolitis). Pediatric SBS is defined as the loss of
≥70% of small intestinal length (either congenital or acquired), equating to no more than
75 cm of the small intestine remaining in a full-term neonate [69]. One population-based
estimate of neonatal SBS reports 24.5 cases per 100,000 live births [91] and mortality
rates of SBS are consistently reported at 20-40% [78, 85, 91].
Despite high mortality rates, major advances have been made to increase the
lifespan of those suffering from SBS. Introduction of parenteral nutrition (PN) is
important for survival and has transformed the management of pediatric SBS [75]. PN
bypasses gastric digestion and provides a complete source of nutrients, vitamins, and
electrolytes intravenously. PN support allows time for intestinal adaptation of the residual
bowel to occur [66]. However, the process of intestinal adaptation is unpredictable and
pediatric patients receiving long-term PN often face life-threatening complications,
including PN-associated liver disease and catheter-related sepsis.
Small bowel transplantation (SBT) is considered a last-resort treatment option for
pediatric patients with extreme SBS or those suffering life-threatening complications
from PN [42]. Since 1990, when the first successful intestinal transplant was documented
[30], intestinal transplants have been successfully employed and survival rates have
steadily increased [86]. Small bowel transplants have a one-year graft and recipient
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survival rate of 62-86% in pediatric patients [58]. Additionally, SBT is a cost-effective
treatment option. Beyond the first year, average costs associated with SBT can be less
than the average costs of prolonged PN [33, 75, 80].
However, two important factors exist when patients are selected to receive a SBT:
1) increased immunosuppressive therapy to preclude immune rejection of the
transplanted tissue and 2) microbial colonization of the recipient and/or donor allograft
[86]. SBT recipients have a higher incidence of allograft rejection than other solid-organ
transplants, due to the high immunogenicity of the bowel, and therefore require more
potent immunosuppression therapy [64]. Breakdown and loss of the mucosal barrier
during episodes of allograft rejection or breach of the gastrointestinal tract during surgery
can translocate enteric organisms from the recipient or donor bowel into circulation,
consequently causing bloodstream infections. Bloodstream infections are common
complications after intestinal transplant and represent a major cause of morbidity and
mortality among SBT recipients. In one study, 70% of pediatric SBT recipients
developed a bloodstream infection within one year after transplantation [24].
Enterococcus, Klebsiella, and Candida were the main causes of infection. Prevention of
translocation-associated infections remains a significant challenge, despite improvements
in antirejection and antimicrobial therapy.
Candida species are the fourth most common cause of hospital-acquired
bloodstream infections in the United States [95]. Candida species including C. albicans,
C. dubliniensis, C. glabrata, C. krusei, C. metapsilosis, C. parapsilosis, and C. tropicalis
are normal, asymptomatic residents of the gastrointestinal and reproductive tract and skin
of most individuals. In healthy individuals, carriage of C. albicans is estimated to be 30-
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60% [52]. However, Candida species can also act as opportunistic pathogens that are
capable of infecting a broad range of body sites when host resistance is decreased.
Candida species are responsible for a spectrum of diseases, including mucosal,
cutaneous, and invasive infections.
Of particular concern is when Candida crosses the epithelial barrier and gains
access to the bloodstream, causing candidemia and potentially spreading throughout the
body, causing infections of other organs termed invasive candidiasis (IC). The overall
incidence of IC is estimated at 63,000 cases/year in the United States [63]. This lifethreatening infection is responsible for mortality rates reaching 49% [32] and medical
care costs of an estimated $1.7 billion per year [94]. IC continues to be a persistent public
health problem and infections due to Candida are the most common and fatal fungal
bloodstream infections among pediatric SBT recipients [23].
Patients receiving solid organ transplantations present a unique combination of
risk factors that predispose them to develop fungal bloodstream infections with Candida.
In particular, pediatric SBT recipients constitute a population with an increased incidence
for IC, with up to 25% of recipients developing invasive candidiasis [23]. Risk factors for
candidemia among SBT recipients include immunosuppressive therapies, broad-spectrum
antibiotics, use of central venous catheters, invasive abdominal surgery, environmental
hospital exposures, and repeated endoscopy surveillance [25, 71, 76]. In addition, these
patients experience disruption of the gastrointestinal barrier during surgery and the
introduction of a foreign microbiota with the donor allograft.
The Candida implicated in candidemia may be of endogenous or exogenous
origin [31]. Candidemia is often believed to derive from an endogenous source, as many
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individuals harbor Candida species in their gastrointestinal tract. The carriage of Candida
in the donor or remnant recipient organ may act as a reservoir for pathogenic fungi and an
endogenous source of IC [76]. Donor organs can also carry commensal Candida or may
become infected during hospitalization of the donor or during procurement and
preservation of the organ [31, 39]. Transplantation of an infected organ can serve as
another possible source of infection.
There is now increasing evidence for exogenous sources of Candida originating
from the hospital environment, contaminated implanted medical devices, or from the
skin. Infection with C. parapsilosis is often linked to an exogenous source because of its
ubiquity in the environment and its presence on the skin of healthy humans. Carriage of
C. parapsilosis on the hands of health care workers has long been recognized [38] and
plays an important role in the transmission of opportunistic yeasts to hospitalized
patients. Horizontal spread of C. parapsilosis infections from nurses to infants has been
documented [37, 47]. In addition, nosocomial infections with C. parapsilosis are related
to the contamination of indwelling central venous catheters used for the administration of
PN [55]. The ability of C. parapsilosis to produce biofilms on catheter instruments is a
common cause of IC because it gives the yeast direct access into the bloodstream upon
insertion [13, 45].
Molecular typing methods have proven to be valuable to analyze strain
relatedness in order to perform epidemiological assessment of candidiasis outbreaks. Two
classes of typing methods exist for molecular characterization of Candida species—nonDNA-based and DNA-based [73]. The first class, non-DNA-based, includes strain typing
that indirectly assays the genotype by multilocus enzyme electrophoresis (MLEE).
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MLEE is a method that assesses and compares multiple core metabolic enzyme
fingerprints by analyzing their electrophoretic mobilities on a gel. While MLEE has
shown to be highly discriminatory and reproducible, this method assays the genome
indirectly, may take several days to complete, and is difficult to master [10, 15, 73].
The second class of molecular typing methods for Candida species is DNA-based.
Conventional DNA-based techniques used to genotype Candida in epidemiological
studies include electrophoretic karyotyping with pulsed-field gel electrophoresis (PFGE),
restriction enzyme analysis (REA) with Southern blotting, random amplified
polymorphic DNA (RAPD), and amplified fragment length polymorphism (AFLP) [3, 5,
9, 49, 65]. These methods have the potential to discriminate at the strain level, but
potential drawbacks associated with these methods include low reproducibility, low
discriminatory power, and the need for trained personnel [73].
The conventional DNA-based techniques described above allow for easy strain
differentiation within a laboratory; however, comparison of data between laboratories is
nearly impossible. Therefore, exact DNA-based methods that are more unambiguous and
reproducible, such as multilocus sequence typing (MLST), offer the best way at present
to strain-type Candida [11]. MLST has been successfully applied to several Candida
species including C. albicans, C. glabrata, C. krusei, and C. tropicalis, but not C.
parapsilosis [12, 22, 40, 81, 82]. MLST protocols are based on the analysis of nucleotide
sequence polymorphisms in 400- to 500-bp internal fragments of 6-8 independent
housekeeping genes. MLST is a robust typing technique because of the highly
reproducible nature of the data generated and allows for laboratories to easily compare
and exchange data. Internet databases have been constructed for a number of organisms,
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including multiple Candida species, and allow for the sharing of global epidemiological
data (http://www.mlst.net/databases/). Many Candida epidemiological studies using
MLST have been reported and show the method to be highly discriminating and stable
[70, 90]. Ultimately, it is recommended to employ at least two independent techniques to
verify the results for a set of given isolates [87].
The prevention and treatment of candidemia among SBT recipients is
controversial [31]. Antifungal prophylaxis is appealing for recipients of organ transplants
due to the high mortality rate of invasive fungal bloodstream infections post-transplant.
However, extensive use of antifungal prophylaxis selects for resistant Candida species.
The recent emergence of azole-resistant species (C. glabrata and C. krusei) is likely due
to widespread use of fluconazole and other antifungal agents [77]. Additionally, a shift
towards non-albicans Candida species causing fungemia has been observed [79].
Fluconazole is routinely used for antifungal prophylaxis; however, choice of drug,
who should receive it, and when to initiate/discontinue prophylaxis is not well
understood, therefore, universal use cannot be justified to all transplant recipients [77].
Antifungal prophylaxis should ideally be based on institutional trends. Established
candidiasis infections are routinely treated with amphotericin B, azoles, and
echinocandins [59]. Problems associated with antifungal treatments include potential
toxicity, drug interactions with immunosuppressant agents, high costs, and patient
compliance. Also, poor compliance with current antifungal management guidelines by
transplant physicians has been documented [53].
Small bowel transplantation is a life-preserving treatment for pediatric short
bowel syndrome patients facing intestinal failure or life-threatening complications from
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parenteral nutrition. Recipients of SBT represent a population of patients with a
combination of unique risk factors, making them highly susceptible to fungal
bloodstream infections, mainly caused by Candida species. Thus, it is essential to
identify exogenous or endogenous Candida yeasts implicated in infection and understand
their origin in order to improve survival rates and prevent fungal infections for recipients
of small bowel transplants. Clinicians must understand the epidemiology of Candida in
their institution and know which Candida species are implicated in infection in order to
select appropriate treatment options for their patients.
To our knowledge, no studies have investigated the intestinal microbiota or origin
of Candida causing candidemia in SBT recipients. In the present work, we defined the
gut mycobiota of SBT recipients and genotyped ileum and bloodstream isolates to infer
origin of infection. We also assessed isolates to determine if patients shared the same
strains of Candida. The data obtained in this study will contribute to the knowledge base
of Candida epidemiology and infections acquired by SBT recipients at the University of
Nebraska Medical Center.

3.3 MATERIALS AND METHODS
Sample collection
A total of seven pediatric short bowel syndrome patients who received small
bowel transplantations and later developed candidemia at the University of Nebraska
Medical Center were included in this study. The patient cohort comprised 3 females and
4 males with a mean age of 23.1 months (median: 20 months; range: 16-37 months). The
University of Nebraska Medical Center is a premier facility for SBT, conducting ~20
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transplants per year. Ileostomy and blood samples were collected from recipients under
UNMC Institutional Review Board protocol #417-02, and informed consent was received
from the caregivers of all patients. Candidemia was diagnosed on the basis of symptoms
and a positive blood culture identified using the API 20C test (BioMérieux, Marcy
l’Etoile, France). Ileostomy samples prior to and concurrent with infection (up to nine)
were collected post-transplantation during hospitalization and stored at -80°C until
processing (Table 3.1). Culture positive bloodstream isolates from each recipient
following infection were isolated and maintained on Sabouraud dextrose agar.

Extraction of DNA from Ileostomy Samples
DNA was extracted from ileostomy samples following the protocol of Oh and
colleagues [57]. Briefly, 300 μl of ileal effluent was centrifuged at 10,000 x g for 5
minutes. Cell pellets were resuspended with 750 μl lysis buffer (200 mM NaCl, 100 mM
Tris [pH=8.0], 20 mM EDTA, 20 mg/mL lysozyme) and transferred to a 2 ml tube
containing 300 mg of 0.1-mm zirconium beads (BioSpec Products). Cell suspensions
were incubated at 37°C for 45 minutes and 85 μl of 10% sodium dodecyl sulfate and 40
μl of proteinase K (15 mg/ml) was added. Samples were then incubated for 45 minutes at
60°C. After the second incubation, 500 μl of phenol-chloroform-isoamyl alcohol
(25:24:1) was added, and the samples were bead beaten at maximum speed for 2 minutes
and immediately cooled on ice. Samples were centrifuged at 13,500 x g for 5 minutes and
the top aqueous layer was extracted once with phenol-chloroform-isoamyl alcohol
(25:24:1) and twice with chloroform-isoamyl alcohol. DNA was precipitated by the
addition of 2.5 volumes of 100% ethanol, 1/10 volume of 3M sodium acetate (pH 5.2)
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and 50 μg/ml GlycoBlue (Ambion) at -20°C overnight. The samples were centrifuged at
full speed for 25 minutes and the resulting DNA pellets were washed with 70% ethanol,
air-dried, and dissolved in 50 μl sterile water.

Isolation of yeasts from ileostomy samples
To obtain pure culture isolates from ileostomy samples, approximately 250 μl of
ileal effluent was grown overnight at 37°C with shaking (200 rpm) in yeast nitrogen
broth (YNB; 6.7 g/L yeast nitrogen base, 10 g/L glucose, 0.76 g L-asparagine, 50 mg/L
chloramphenicol, 20 mg/L gentamicin sulfate, sterilized by filtration) and yeast extract
peptone dextrose broth (YPD; 10 g/L yeast extract, 20 g/L peptone, 20 g/L glucose, 50
mg/L chloramphenicol, pH 5.6). Volumes of 100 μl were plated after 24, 48, and 72
hours on YPD (supplemented with 50 mg/L chloramphenicol), CHROMagar Candida
(Paris, France), potato dextrose agar (PDA, Oxoid; supplemented with 50 mg/L
chloramphenicol), and dichloran rose bengal chloramphenicol (DRBC; 10 g/L glucose, 5
g/L peptone, 1 g/L monopotassium phosphate, 0.5 g/L magnesium sulfate, rose bengal
0.025 g/L, dichloran 0.002 g/L chloramphenicol 0.10 g/L). Plates were incubated at 37°C
and monitored daily for 2 weeks. Multiple colonies from each plate were further isolated
on the basis of color and morphology and maintained at 4°C.
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Table 3.1 Outline of patients and sample collection.
Patient

Age

Sex

P32

28 mo.

F

P33

37 mo.

F

P39

23 mo.

M

P47

20 mo.

F

P62

16 mo.

M

P74

20 mo.

M

P88

18 mo.

M

Sample Name

Date of Collection

Source of Sample

32_I_1
32_B_1
33_I_1
33_I_2
33_B_1
33_I_3
39_I_1
39_B_1
39_I_2
47_I_1
47_I_2
47_I_3
47_B_1
47_I_4
47_I_5
47_B_2
47_I_6
47_I_7
47_I_8
47_I_9
62_I_1
62_I_2
62_B_1
62_I_3
62_I_4
62_I_5
74_I_1
74_I_2
74_B_1
74_I_3
74_I_4
74_B_2
74_I_5
74_I_6
88_B_1
88_I_1
88_I_2

18 Mar 2005
28 Mar 2005
15 Aug 2005
29 Sept 2005
7 Oct 2005
24 Mar 2006
7 June 2004
8 Oct 2004
22 Oct 2004
13 Sept 2004
24 Sept 2004
28 Sept 2004
30 Sept 2004
1 Oct 2004
5 Oct 2004
6 Oct 2004
12 Oct 2004
19 Oct 2004
27 Oct 2004
1 Nov 2004
14 July 2005
22 July 2005
30 July 2005
2 Aug 2005
2 Sept 2005
7 Oct 2005
22 June 2006
12 July 2006
20 July 2006
3 Oct 2006
27 Oct 2006
7 Nov 2006
15 Nov 2006
17 Nov 2006
3 Jan 2007
4 Jan 2007
16 Jan 2007

Ileostomy
Blood
Ileostomy
Ileostomy
Blood
Ileostomy
Ileostomy
Blood
Ileostomy
Ileostomy
Ileostomy
Ileostomy
Blood
Ileostomy
Ileostomy
Blood
Ileostomy
Ileostomy
Ileostomy
Ileostomy
Ileostomy
Ileostomy
Blood
Ileostomy
Ileostomy
Ileostomy
Ileostomy
Ileostomy
Blood
Ileostomy
Ileostomy
Blood
Ileostomy
Ileostomy
Blood
Ileostomy
Ileostomy
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Extraction of DNA from pure culture bloodstream and ileal Isolates
DNA was extracted from ileal and bloodstream isolates following the protocol of
Harju et al. [34]. Yeast colonies were grown overnight at 37°C in YPD medium (1%
yeast extract, 2% peptone, 2% glucose) with 200 rpm shaking and pelleted by
centrifugation at 20,000 x g for 2 minutes. Pellets were resuspended in 200 μl of Harju
lysis buffer (2% Triton X-100, 1% SDS, 100 mM NaCl, 10 mM Tris-HCl [pH 8.0], 1
mM EDTA [pH 8.0]). The samples were frozen at -80°C for 10 minutes and then
immersed into a 95°C water bath for 1 minute. The freeze/thaw process was repeated.
Sterile pestles were used to disrupt cell walls, and then samples were vortexed vigorously
for 30 seconds. After the addition of 200 μl of chloroform and 2 minutes of vortexing,
samples were centrifuged at 20,000 x g for 3 minutes. The upper aqueous layer was
transferred into a microcentrifuge tube containing 400 μl of ice-cold 100% ethanol,
mixed with inversion, and incubated at -20°C for at least 10 minutes. The samples were
centrifuged again at 20,000 x g for 5 minutes. DNA pellets were washed with 500 μl icecold 70% ethanol followed by air-drying at room temperature. DNA was dissolved in 50
μl sterile water.

Genomic amplification
The extracted DNA from each ileostomy sample and isolate was selectively
amplified by PCR using fungal‐specific primers ITS1-F (5’-CTTGGTCATTTAGA
GGAAGTAA-3’) and ITS4 (5’-TCCTCCGCTTATTGATATGC-3’) [27, 93]. PCR
reaction mixtures consisted of 1.25 U of TaKaRa Ex Taq (Shiga, Japan), 5 μl of 10X Ex
Taq buffer, 4 μl of dNTP mixture (2.5 mM each), 20 pmol of each primer, and 1 μl of
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genomic DNA. Amplifications were performed with the following PCR cycling
conditions: initial denaturation at 94°C for 4 minutes, followed by 30 cycles of
denaturation at 94°C for 30 seconds, annealing at 52°C for 1 minute, elongation at 72°C
for 1.5 minutes and a final extension step at 72°C for 10 minutes. PCR amplicons were
separated using a 0.7% agarose gel in 1 x TAE buffer and visualized with 0.5 μg/ml
ethidium bromide staining.

Cloning and sequencing
PCR products from ileostomy samples were cloned using the pGEM® -T Easy
Vector System Kit (Promega, Lyon, France) following the manufacturers instructions to
obtain a profile of the intestinal fungi. For each sample, 25 colonies negative for βgalactosidase activity were chosen and those with distinct EcoR1 patterns were
sequenced on an ABI 3730xl platform at Michigan State University’s Research
Technology Support Facility (East Lansing, MI). Fungal sequences were identified by
sequence homology using nucleotide BLAST against the UNITE curated fungal ITS
sequence database [44] and the curated FUNCBS database, as accessed through the
Centraalbureau voor Schimmelcultures
(www.cbs.knaw.nl/Collections/BioloMICSSequences.aspx?file=all; accessed September
2014).

Multilocus sequence typing
All C. albicans and C. glabrata ileostomy and bloodstream isolates were typed by
MLST as described previously [12, 22] (Table 3.2). MLST protocols are not currently
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available for C. parapsilosis. For C. albicans, seven housekeeping gene fragments were
sequenced (AAT1a, ACC1, ADP1, MPIb, SYA1, VPS13, ZWF1b). For C. glabrata, six
housekeeping gene fragments were sequenced (FKS, LEU2, NMT1, TRP1, UGP1,
URA3). Each gene fragment was amplified using 50 μl PCR reactions containing 100 ng
of genomic DNA, 1.25 U of TaKaRa Ex Taq (Shiga, Japan), 5 μl of 10X Ex Taq buffer, 4
μl of dNTP mixture (2.5 mM each), and 25 pmol of each primer (Table 3.2). PCR
conditions for C. albicans MLST reactions were as follows: 94°C for 5 minutes, followed
by 30 cycles of 94°C for 1 minute, relevant annealing temperature (Table 3.2) for 1
minute, and 72°C for 1 minute, with a final extension period of 10 minutes at 72°C. PCR
conditions for C. glabrata MLST reactions were as follows: 94°C for 7 minutes, followed
by 30 cycles of 94°C for 1 minute, relevant annealing temperature (Table 3.2), and 74°C
for 1 minute, with a final extension period of 10 minutes at 74°C.
All PCR products were purified using the Wizard SV Gel and PCR Clean-up Kit
(Promega, Madison, WI). Following cleanup, amplicons were sequenced in both
directions using the same primers used for PCR. Sequences were aligned and assembled
using ClustalW implemented in BioEdit Sequence Alignment Editor version 7.3.2. For C.
albicans, heterozygosities were assessed by visual inspection of the chromatograms and
designated using the International Union of Pure and Applied Chemistry nomenclature
[12]. Sequences were entered into the MLST databases (http://pubmlst.org/calbicans/ &
http://cglabrata.mlst.net/) and assigned an allele profile for each locus and an overall
sequence type (ST).
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Table 3.2 C. albicans and C. glabrata MLST schemes.
Locus

Gene product

Primer sequence (5’-3’)

C. albicans
AAT1a
Asparate
aminotransferase

F: ACTCAAGCTAGATTTTTGGC

ACC1

Acetyl-coenzyme A
carboxylase

F: GCAAGAGAAATTTTAATTCAATG

ADP1

ATP-dependent
permease

F: GAGCCAAGTATGAATGATTTG

Mannose phosphate
isomerase

F: ACCAGAAATGGCCATTGC

Alanyl-RNA synthetase

F: AGAAGAATTGTTGCTGTTACTG

MPIb
SYA1

Annealing
Temp (°C)

No. bp
sequenced

52

373

55

407

55

443

52

375

55

391

55

403

52

491

55

589

54

512

59

607

50

419

57

616

53

602

R: CAGCAACATGATTAGCCC
R: TTCATCAACATCATCCAAGTG
R: TTGATCAACAAACCCGATAAT
R: GCAGCCATGCATTCAATTAT
R: GTTACCTTTACCACCAGCTTT

VPS13

Vacuolar protein sorting
protein

F: TCGTTGAGAGATATTCGACTT

ZWF1b

Glucose-6-phosphate
dehydrogenase

F: GTTTCATTTGATCCTGAAGC

C. glabrata
FKS
1,3-Beta-glucan synthase

R: ACGGATGGATCTCCAGTCC
R: GCCATTGATAAGTACCTGGAT
F: GTCAAATGCCACAACAACAACCT
R: GCACTTCAGCAGCGTCTTCAG

LEU2

3-Isoprpylmalate
dehydrogenase

F: TTTCTTGTATCCTCCCATTGTTCA

NMT1

Myristoyl-CoA, protein
N-myristoyltransferase
CoA
Phosphoribosylanthranilate isomerase

F: GCCGGTGTGGTGTTGCCTGCTC

UTP-glucose-1phosphate
uridylyltransferase
Orotidine-5’phosphate
decarboxylase

F: TTTCAACACCGACAAGGACACAGA

TRP1
UGP1

URA3

R: ATAGGTAAAGGTGGGTTGTGTTGC
R: CGTTACTGCGGTGCTCGGTGTCG
F: AATTGTTCCAGCGTTTTTGT
R: GACCAGTCCAGCTCTTTCAC
R: TCGGACTTCACTAGCAGCAAATCA
F: AGCGAATTGTTGAAGTTGGTTGA
R: AATTCGGTTGTAAGATGATGTTGC
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Random amplified polymorphic DNA
C. albicans, C. glabrata, and C. parapsilosis isolates were also typed by RAPD
using the primer Oligo 2 (5’-TCACGATGCA-3’) as described previously [9]. C.
parapsilosis isolates were further typed with the primer OPE-04 (5’-GTGACATG-3’)
[8]. Additional control Candida strains were added to each RAPD reaction to test
discriminatory power. Amplification reactions were performed as described above for
PCR with 10 ng of genomic DNA. PCR was performed as follows: 94°C for 5 minutes,
followed by 40 cycles of 94°C for 30 seconds, 36°C for 30 seconds, and 72°C for 2
minutes, with a final extension period of 10 minutes at 72°C. PCR amplicons were
separated using a 1.5% agarose gel in 1x TAE buffer at 80 V for 90 min and visualized
with 0.5 g/ml ethidium bromide staining. Isolates were considered distinct if banding
patterns differed.

Antifungal susceptibility test
Antifungal susceptibility was assessed using a commercially available
colorimetric microdilution panel Sensititre YeastOne YO-9 (TREK Diagnostic Systems).
The Sensititre YeastOne system provides antifungal susceptibility testing and minimum
inhibitory concentration (MIC) determination against nine antifungals: amphotericin B
(0.12 – 8 µg/ml), 5-flucytosine (0.06 – 64 µg/ml), anidulafungin (0.015 – 8 µg/ml),
caspofungin (0.008 – 8 µg/ml), micafungin (0.008 – 8 µg/ml), fluconazole (0.12 – 256
µg/ml), itraconazole (0.015 – 16 µg/ml), posaconazole (0.008 – 8 µg/ml), and
voriconazole (0.008 – 8 µg/ml). Testing was carried out following the manufacturers
instructions. After 24-48 hours of incubation, panels were observed and MIC end points
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were determined as evidenced by a color change from blue to red. Isolates were
categorized according to the CLSI breakpoints (CLSI) reported by the manufacturer.
Breakpoints were not available for posaconazole and amphotericin B, therefore, isolates
inhibited by >1 mg/ml of amphotericin B and >1 mg/ml of posaconazole were considered
resistant [26, 61].

3.4 RESULTS
Prevalence of Candida in ileal effluent from SBT recipients
Profiling fungi of the ileum revealed that SBT recipients harbored several
Candida and non-Candida species (Table 3.3). C. albicans was the most predominant
species, detected in the ileum of four patients (57%) and 11 out of 28 ileostomy samples
(40%). C. glabrata was identified in three patients and 10 samples (35%). C. parapsilosis
was obtained from two patients and six samples (21%). C. tropicalis was detected in two
samples (7%) from two patients (28%) and C. lusitaniae (also known as Clavispora
lusitaniae) was detected in one patient (14%), one sample (3.5%). Two patients (P33 and
P62) harbored three species of Candida in the ileum and two patients (P47 and P74)
harbored 2 species of Candida in the ileum. P32 and P39 each harbored one species of
Candida. No Candida was detected in the ileum of P88.

Yeasts causing bloodstream infection in SBT recipients
Species taxonomic classification was determined for each blood culture and the
results are shown in Table 3.3. With the exception of P62, all bloodstream infections
were caused by Candida. C. parapsilosis was the most predominant species isolated from
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the bloodstream of the patient group (3 patients). C. albicans was the second mostisolated species from the bloodstream, in two patients, while C. glabrata, C.
orthopsilosis, and Wickerhamomyces anomalus (formerly Pichia anomala) were each
isolated from one patient. P74 showed positive blood cultures of two different yeasts (C.
parapsilosis and C. albicans).

Table 3.3 Identification of fungi in ileostomy and blood samples.
Sample
32_I_1

Candida ileal species

Non-Candida ileal species

C. albicans

Epicoccum nigrum, Penicillium
cf. roqueforti, Acremonium sp.

32_B_1

C. parapsilosis*

33_I_1

C. albicans

33_I_2

C. albicans*

Penicillium cf. roqueforti,
Cladosporium sp., Pichia
kudriavzevii
Pichia kudriavzevii

33_B_1
33_I_3
39_I_1

C. albicans*
C. albicans, C. glabrata.
C. tropicalis*
C. glabrata*

Pichia kudriavzevii *

39_B_1
39_I_2

C. glabrata*
C. glabrata*

47_I_1
47_I_2

C. parapsilosis

47_I_3

C. parapsilosis,
C. glabrata*

Epicoccum nigrum, Penicillium
cf. roqueforti
Debaryomyces sp., Trichoderma
sp., Penicillium cf. roqueforti
C. glabrata

47_B_1
47_I_4
47_I_5

C. parapsilosis*
C. parapsilosis*
C. glabrata*
C. parapsilosis,
C. glabrata*

47_B_2
47_I_6

Blood isolate

Penicillium cf. roqueforti
Penicillium cf. roqueforti
C. parapsilosis*

C. glabrata
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Table 3.3 Continued.
Sample

Candida ileal species

47_I_7

C. glabrata*

47_I_8

C. glabrata

47_I_9

C. parapsilosis,
C. glabrata*

62_I_1
62_I_2

Non-Candida ileal species

Blood isolate

Penicillium cf. roqueforti
C. albicans

Fusarium sp., Penicillium cf.
roqueforti

62_B_1

W. anomalus*

62_I_3

C. albicans, C. tropicalis

62_I_4

C. albicans, C. parapsilosis*

62_I_5

C. albicans

Penicillium cf. roqueforti

74_I_1

C. albicans

Penicillium cf. roqueforti

74_I_2

Penicillium cf. roqueforti,
Fusarium sp., Debaryomyces
hansenii, Pichia fermentens

Penicillium cf. roqueforti

74_B_1

C. parapsilosis*

74_I_3

C. albicans, C. lusitaniae

74_I_4

C. albicans

Epicoccum nigrum, Penicillium
cf. roqueforti

74_B_2

C. albicans*

74_I_5

Aureobasidium pullulans

74_I_6

Saccharomyces cerevisiae

88_B_1

C. orthopsilosis*

88_I_1

Penicillium cf. roqueforti

88_I_2

Epicoccum nigrum, Penicillium
cf. roqueforti, Saccharomyces
cerevisiae, Pichia kudriavzevii

*Obtained in culture
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MLST analysis of isolates
All C. albicans (n=3) and C. glabrata (n=8) isolates were subjected to MLST and
results are shown in Table 3.4 and Table 3.5. Two sequence types were identified for
each species. Twelve alleles were identified among the seven loci of C. albicans isolates,
including two new alleles, which generated a new, unique diploid sequence type.
Fourteen polymorphic nucleotide sites were found between the two C. albicans sequence
types. Both C. albicans sequence types detected in this study (ST2854 & ST2855) are
novel isolates and have been deposited in the MLST database. Additionally, two
sequence types (ST2 & ST3), consisting of 12 alleles and 23 variable nucleotide sites
were identified among the six loci of C. glabrata isolates.
For P33, ileostomy and blood C. albicans isolates yielded one sequence type
(ST2854). C. albicans causing bloodstream infection in P74 was sequence type 2855,
distinct from P33. C. glabrata ileostomy and bloodstream isolates from P39 shared
sequence type 3. P47, who developed candidemia by C. parapsilosis, had gastrointestinal
colonization by C. glabrata. However, the C. glabrata isolated from this individual had a
sequence type 2, which was a distinct genotype from P39. In both species for which
MLST was possible, sequence type and thus strain was consistent within a patient over
time, but differed between patients.
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Table 3.4 MLST genotypes of C. albicans isolates studied.
Allele number
AAT1a

ACC1

ADP1

MPIb

SYA1

VPS13

ZWF1b

MLST
Genotype

33_I_2

156

4

4

4

204

4

4

2854

33_B_1

156

4

4

4

204

4

4

2854

74_B_2

35

7

6

4

4

4

239

2855

Sample

Table 3.5 MLST genotypes of C. glabrata isolates studied.
Allele number
FKS

LEU2

NMT1

TRP1

UGP1

URA3

MLST
Genotype

39_I_1

5

7

8

7

3

6

3

39_B_1

5

7

8

7

3

6

3

39_I_2

5

7

8

7

3

6

3

47_I_3

1

2

2

1

1

1

2

47_I_4

1

2

2

1

1

1

2

47_I_5

1

2

2

1

1

1

2

47_I_7

1

2

2

1

1

1

2

47_I_9

1

2

2

1

1

1

2

Sample

RAPD analysis of isolates
RAPD fingerprinting with primer Oligo 2 was performed on all cultured C.
albicans and C. glabrata isolates (Figure 3.1 and Figure 3.2). Four C. albicans isolates
generated three different RAPD profiles. C. albicans isolates recovered from the
ileostomy and bloodstream of P33 had the same RAPD profile, A. The bloodstream
isolate from P74 gave a distinct RAPD profile, B (C. albicans was detected in ileostomy
samples from P74 but could not be cultured). The common laboratory strain C. albicans
SC5314 also gave a distinct pattern, C. Nine C. glabrata isolates generated three different
RAPD profiles. C. glabrata isolates obtained from the ileostomy and bloodstream of P39
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all had same RAPD profile D. C. glabrata ileostomy isolates from five consecutive
ileostomy samples over a one month period in P47 generated RAPD profile E, while
control strain C. glabrata NRRL Y-65 gave a distinct RAPD pattern F. The RAPD results
obtained from C. albicans and C. glabrata isolates are congruent with strain typing data
by MLST (Table 3.6). No RAPD patterns for C. albicans or C. glabrata were shared
across individuals.

Figure 3.1 RAPD fingerprint patterns of C. albicans isolates obtained with primer
Oligo 2. Fingerprints indicated with the same letter have equal genotypes. Arrows
indicate fragments found in any profiles of the strains. First lane 1 KB+ molecular size
marker. Laboratory strain C. albicans SC5314 included with isolates.
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Figure 3.2 RAPD fingerprint patterns of C. glabrata isolates obtained with primer
Oligo 2. Fingerprints indicated with the same letter have equal genotypes. Arrows
indicate fragments found in any profiles of the strains. First lane 1 KB+ molecular size
marker. C. glabrata NRRL Y-65 included with isolates.

In addition, RAPD was performed on C. parapsilosis isolates with primer Oligo 2
(Figure 3.3). Seven C. parapsilosis isolates generated two different RAPD profiles. P47
C. parapsilosis isolates showed two distinct RAPD patterns between ileostomy and
bloodstream. The two C. parapsilosis blood cultures were collected from this patient
before and after the ileostomy sample. Both blood cultures generated the same RAPD
pattern H. However, the ileostomy isolate showed RAPD pattern G. Interestingly, the two
ileostomy samples prior to the first bloodstream collection harbored C. parapsilosis, but
viable organisms could not be cultured. Three C. parapsilosis isolates, collected from the
ileostomy of P62 and the blood of P32 and P74, gave the same RAPD pattern G. Control
C. parapsilosis 232, isolated from cheese, also gave the RAPD pattern G. Since a C.
parapsilosis MLST scheme does not exist, primer OPE-04 was also used for RAPD to

123
confirm or contradict results obtained by primer Oligo 2. Primer OPE-04 likewise yielded
two different patterns among the seven isolates, in agreement with primer Oligo 2 (Figure
3.4).

Figure 3.3 RAPD fingerprint patterns of C. parapsilosis isolates obtained with
primer Oligo 2. Fingerprints indicated with the same letter have equal genotypes.
Arrows indicate fragments found in any profiles of the strains. First lane 1 KB+
molecular size marker. C. parapsilosis 232 isolated from cheese included with isolates.

Figure 3.4 RAPD fingerprint patterns of C. parapsilosis isolates obtained with
primer OPE-04. Fingerprints indicated with the same shape have equal genotypes.
Arrows indicate fragments found in any profiles of the strains. First lane 1 KB+
molecular size marker. C. parapsilosis 232 isolated from cheese included with isolates.
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Table 3.6 Genotype of cultured ileal (I) and bloodstream (B) isolates.
Sample
32_B_1
33_I_2
33_B_1
39_I_1
39_B_1
39_I_2
47_I_3
47_B_1
47_I_4
47_I_5
47_I_7
47_B_2
47_I_9
62_I_4
74_B_1
74_B_2
Control
Control
Control

Culture
C. parapsilosis
C. albicans
C. albicans
C. glabrata
C. glabrata
C. glabrata
C. glabrata
C. parapsilosis
C. parapsilosis
C. glabrata
C. glabrata
C. glabrata
C. parapsilosis
C. glabrata
C. parapsilosis
C. parapsilosis
C. albicans
C. albicans
C. glabrata
C. parapsilosis

RAPD genotype
G
A
A
D
D
D
E
H
G
E
E
E
H
E
G
G
B
C
F
G

MLST genotype
n/a
2854
2854
3
3
3
2
n/a
n/a
2
2
2
n/a
2
n/a
n/a
2855
n/a
n/a
n/a

The chronological carriage of Candida genotyping patterns is reported in Figure
3.5. At two points, samples were collected from multiple patients during the same time
period. In both cases, patients carried distinct strains from one another. C. parapsilosis
isolates of RAPD profile G were detected consistently over time in four patients. Isolates
of all other MLST and RAPD profiles were each restricted to a single patient, in our
sampling. No one genotype dominated the patient population.

Figure 3.5 Chronological outline of patient sample collection. The MLST sequence types and RAPD profiles are indicated for each
patient.
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Antifungal susceptibility
The antifungal susceptibilities and MICs for the yeast isolates against nine
antifungals using the YeastOne system are shown in Table 3.7. C. glabrata isolate
39_B_1 was classified as susceptible dose-dependent to fluconazole and voriconazole
based on MIC interpretative criteria from the manufacturer. This isolate showed
multidrug resistance against amphotericin B, itraconazole, and posaconazole. C.
parapsilosis isolates 47_B_1 and 47_B_2 were resistant to amphotericin B. C. albicans,
C. orthopsilosis, and W. anomalus isolates were uniformly susceptible to all antifungals.
For all isolates, the range of MICs were: amphotericin B (0.25-2 μg/ml), itraconazole
(0.06-2 μg/ml), posaconazole (0.03-2 μg/ml), and voriconazole (0.03-2 μg/ml).
Fluconazole showed a wide range of MICs among the isolates (0.5-32 μg/ml), as well as
micafungin (<0.008-2 μg/ml), anidulafungin (0.015-2 μg/ml), and caspofungin (0.015-2
μg/ml). 5-flucytosine showed a narrow range of MICs among the isolates (<0.06-0.25
μg/ml).

Table 3.7 Summary of MIC values and antifungal susceptibility of bloodstream isolates determined by YeastOne.
MIC1 (μg/ml) & Susceptibility2
Isolate

AB

AND

CAS

FC

FZ

IZ

MF

PZ

VOR

MIC

S

MIC

S

MIC

S

MIC

S

MIC

S

MIC

S

MIC

S

MIC

S

MIC

S

33_B_1

1

S

0.03

S

0.03

S

0.12

S

0.5

S

0.06

S

0.008

S

0.03

S

0.03

S

74_B_2

1

S

0.03

S

0.03

S

0.12

S

4

S

0.12

S

<0.008

S

0.06

S

0.12

S

2

R

0.06

S

0.25

S

<0.06

S

32

S-DD

2

R

0.015

S

2

R

2

S-DD

1

S

1

S

0.5

S

0.12

S

1

S

0.12

S

0.5

S

0.12

S

0.12

S

32_B_1

1

S

2

S

0.25

S

0.25

S

1

S

0.12

S

1

S

0.06

S

0.03

S

47_B_1

2

R

2

S

2

S

0.12

S

2

S

0.06

S

2

S

0.06

S

0.06

S

47_B_2

2

R

2

S

2

S

0.12

S

2

S

0.06

S

2

S

0.06

S

0.06

S

74_B_1

0.25

S

1

S

0.25

S

0.06

S

1

S

0.06

S

1

S

0.03

S

0.15

S

0.5

S

0.015

S

0.015

S

<0.06

S

2

S

0.06

S

0.015

S

0.12

S

0.06

S

C. albicans

C. glabrata
39_B_1
C. orthopsilosis
88_B_1
C. parapsilosis

W. anomalus
62_B_1
1

AMB, amphotericin B; AND, anidulafungin; CSP, caspofungin; FC, 5-flucytosine; FZ, fluconazole; ITC, itraconazole; MF,
micafungin; PSC, posaconazole; VOC, voriconazole.
2
S, susceptible; S-DD, susceptible dose-dependent; I, intermediate; R, resistant.
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3.5 DISCUSSION
Small bowel transplantation is a life-preserving treatment for pediatric short
bowel syndrome patients facing intestinal failure or life-threatening complications from
parenteral nutrition. The increasing incidence of Candida infections and the high
mortality rates post-transplant warrant further research into the epidemiology of
nosocomial fungal infections. The present study describes a cohort of small bowel
transplant patients who developed bloodstream infection post-transplant at the University
of Nebraska Medical Center from 2004-2007. We employed two molecular typing
methods to determine the potential source of nosocomial candidemia infections in SBT
recipients.
Bloodstream infections in this study were mainly caused by C. parapsilosis
(43%). Prior to 1990, the predominant species causing Candida infections was C.
albicans [62]. In recent years there has been an emergence of infections caused by nonalbicans species [1, 6, 36]. C. albicans was isolated from the bloodstream in only two out
of the seven patients. Non-albicans species caused the majority of infections. C.
orthopsilosis, recently separated from the C. parapsilosis complex with C. metapsilosis
[81], was identified in the bloodstream of one patient. C. orthopsilosis is known to be
responsible for bloodstream infections, however, documented cases are limited [28, 83,
84].
One bloodstream infection was caused by Wickerhamomyces anomalus (formerly
Hansenula anomala and Pichia anomala; teleomorph Candida pelliculosa, current
teleomorph name Candida beverwijkiae). W. anomalus is a ubiquitous yeast found
naturally in the environment and various fermentations. This yeast transiently colonizes
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the oropharyngeal and gastrointestinal tract of humans [16, 54]. W. anomalus is rarely
found as a cause of infection; however, it has been implicated in a few hospital outbreaks
in neonatal and pediatric intensive care units [2, 16, 41, 60]. W. anomalus was not
identified in the intestine of P62 from whom it was isolated from the blood. Therefore, it
is possible that this patient acquired W. anomalus from an exogenous source. Exogenous
acquisition of W. anomalus infection is the suggested route of transmission [2].
This study shows that various species of Candida are present in the
gastrointestinal tract of SBT patients. This is not surprising, as the human gut is known to
harbor multiple Candida species [35]. At least one fungal taxon was found in every
ileostomy sample. Ileostomy samples contained an average of two fungal species and up
to six species in one sample. This is the first study characterizing the fungal intestinal
microbiota of small bowel transplant recipients. It is possible that the cloning method
used to characterize the intestinal mycobiota did not obtain a complete comprehensive
survey of fungi in the ileostomy samples. The number of clones selected for sequencing
and the failure to sequence every clone is a limitation of cloning that may result in
defining a limited diversity. Fungi of low abundance may have not been detected in
ileostomy samples. Moreover, of interest is the fact that all cultured organisms were
detected by molecular cloning, but not vice versa. While next-generation sequencing
methods may describe the complete mycobiota in full, cloning may be the most costefficient and practical way to determine the mycobiota in these patients due to the limited
diversity of gut fungi expected.
We detected previous digestive tract colonization with Candida in six of the
patients with candidemia. Our findings suggest that at least two bloodstream infections
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(P33 and P39) originated from Candida colonizing the gastrointestinal tract. This is in
keeping with the findings of other studies that identified the same strain in the intestine
and blood [19, 43, 51, 67]. Gastrointestinal colonization is an important source of
candidemia, although only a few studies using molecular typing methods exist and
sample numbers are small [55]. Many studies only report an association between
anatomic site of Candida colonization as a risk factor for subsequent candidemia and
invasive candidiasis in hospitalized and critically ill patients [17, 48]. The epidemiology
of candidemia in small bowel transplant recipients has not been previously investigated.
However, it is not surprising that patients in our study were infected by endogenous
Candida due to the invasive nature of this procedure that disrupts the integrity of the
gastrointestinal barrier and allows translocation of microorganisms into the bloodstream.
P47 had different strains of C. parapsilosis colonizing the intestine and infecting
the bloodstream, suggesting that candidemia derived from an exogenous source of C.
parapsilosis. While the possibility of hospital transmission cannot be discounted, other
possibilities exist and include mutation within the patient and increase in prevalence of a
previously-undetectable strain. Microvariation, small detectable changes in DNA
sequence among serial isolates or as separate clones from individual patients, is a known
phenomenon for strains of C. albicans [46, 56]. The majority of documented C.
parapsilosis infections are of exogenous origin. C. parapsilosis is the most common
fungus recovered from the hands and studies have implicated health care workers’ hands
as the source of nosocomial candidemia [50, 88]. Using PFGE and RAPD, Lupetti et al.
[47] demonstrated horizontal transmission of C. parapsilosis infection from the hands of
a health care worker to a newborn. Another study showed dissemination of C.
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parapsilosis between patients and hospital staff, but was unable to determine whether the
initial infection originated in patient or staff [45]. Another possible route of C.
parapsilosis transmission could be contaminated parenteral nutrition and intravascular
devices [18, 21, 92].
C. parapsilosis was not detected in ileostomy samples from P32 and P74, who
developed bloodstream infection with C. parapsilosis. It is possible that these two
individuals exogenously acquired C. parapsilosis. Endogenous C. parapsilosis infections
are rarely seen [51]. P74 was co-infected by two Candida species. C. parapsilosis was
the first organism recovered from the blood, but ileostomy samples show an absence of
C. parapsilosis in the gut prior to infection. Interestingly, C. albicans was present in three
ileostomy samples prior to C. albicans detection in the blood. It is possible that this
patient was infected exogenously by C. parapsilosis and endogenously by the patient’s
own intestinal C. albicans. The inability to culture C. albicans from the patient’s ileum
precluded strain typing and thus confirmation of a possible endogenous source.
Additionally P88, who had no gastrointestinal colonization with C. orthopsilosis, may
have acquired candidemia exogenously.
Studies have documented the ability of Candida isolates to persist in hospital
settings and cause temporally-associated infections [4, 90]. In our study, temporal
analysis revealed multiple species were responsible for causing bloodstream infections
during this time period. At two different time points, samples collected from two patients
overlapped, but the patients did not carry the same genotype. However, the same C.
parapsilosis genotype G in four patients was documented at multiple time points.
Therefore, there is potential evidence that C. parapsilosis strains had a common source.

132
Dissemination could have been due to health care workers, although they are required to
wash hands before and after patient contact as well as wear gloves. Samples from health
care workers or the environment were not taken; however, of potential significance is that
C. parapsilosis isolates of genotype G were detected throughout this study.
Methods used to strain-type Candida species have greatly advanced our
knowledge of fungal epidemiology. MLST and RAPD were applied in this study to help
elucidate the origin of candidemia. MLST has been shown to be more discriminating than
RAPD for C. albicans [70]. In our study, MLST identified distinct isolates between
patients, but did not distinguish between isolates within a patient, whether ileostomy or
bloodstream. This suggests independent, endogenous acquisition of candidemia. Straintyping with RAPD was used as a complement to MLST. RAPD is known to have low
reproducibility but is useful in strain differentiation due to its speed and cost-efficiency.
The fingerprints of the RAPD patterns yielded the same conclusions as MLST for C.
albicans and C. glabrata isolates. Primer Oligo 2 was sufficient to strain-type C. albicans
and C. glabrata.
Since a C. parapsilosis MLST scheme does not exist [81], RAPD was necessary
in order to obtain epidemiological information. RAPD fingerprints generated by both
primer Oligo 2 and OPE-4 gave the same results: one RAPD fingerprint detected in
samples from four patients (as well as a control isolate from cheese), and a distinct
fingerprint in two bloodstream samples from P47, whose ileostomy C. parapsilosis
yielded the other fingerprint. It is possible that other RAPD primers would further
differentiate between our isolates; conversely, genetic variation in C. parapsilosis may be
minimal.
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There is increasing concern regarding antifungal resistance in Candida, especially
C. parapsilosis. A study of a neonatal intensive care unit during a 12-year period showed
that an outbreak of candidemia was caused by a C. parapsilosis strain with fluconazole
resistance due to the long-term use of fluconazole prophylaxis in this institute [74]. In our
study, two C. parapsilosis isolates from the same patient showed resistance to
amphotericin B. MICs reported for C. parapsilosis isolates were within the MIC ranges
in other studies [14, 29]. Usually, C. albicans is susceptible to azoles, echinocandins, and
polyenes [68]; our C. albicans isolates were susceptible to all antifungal agents.
Wickerhamomyces anomalus was susceptible to all antifungals in this study. W. anomalus
does not show intrinsic resistance to any antifungals; however, susceptibility to
itraconazole has been reported to be poor [20].
One of the limitations of this study was the lack of environmental isolates. It was
not possible to determine the exact exogenous source of candidemia in any of the
patients. Also, this study is unable to determine whether the donor bowel was colonized
by Candida and consequently, the source of infection. Donor-derived Candida infections
have been documented in kidney transplant recipients [7, 89]. To date, no efforts have
been made to identify Candida species and/or strains from the donor small bowel to
investigate the origin of candidemia in SBT recipients.
In this study, C. parapsilosis isolates were only typed using RAPD. RAPD is
known to have low reproducibility and may not be the best method for epidemiological
studies. The isolates could not be typed by MLST because attempts to construct a C.
parapsilosis MLST scheme have been unsuccessful thus far due to the lack of sequence
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variation [81]. Other methods such as PFGE-based typing and microsatellite markers may
be more discriminatory for epidemiological investigations of C. parapsilosis [45, 72].
Another limitation of this study was the inability to culture viable organisms from
several ileostomy samples. In some instances a species could be identified by PCR and
sequencing from an ileostomy sample but a subsequent isolate could not be obtained.
Techniques to detect species in mixed matrices are possible with the use of universal or
species-specific primers. Conversely, strain typing aims to differentiate specific strains
and requires pure culture of each isolate [87]. Thus, while we know an ileostomy sample
harbored a specific species, determining intestinal origin could not be elucidated because
of the inability to strain type. However, it must be noted that the samples we used were
collected nearly a decade ago and no special steps had been taken to ensure long-term
survival of microorganisms. The fact that we were able to culture as many isolates as we
were bodes well for future studies with newly-collected material.
In conclusion, these findings highlight the possibility of hospitalized SBT patients
acquiring candidemia both endogenously and exogenously. Although the exact route of
infection in these transplant patients is not clear, our results suggest that cross infection
with C. parapsilosis may have occurred and C. parapsilosis strains of profile G are
frequent and may represent an endemic strain. Attempts need to be aimed at reducing
Candida gut colonization with the use of antimicrobials and antifungals. Also, focused
efforts should be made to ensure proper sterilization of equipment and intravenous
devices. Implementing surveillance programs to ensure correct use of gloves and proper
hand washing is important to prevent spread of infection. Ultimately, these results
underline the importance of Candida surveillance in small bowel transplant institutes and

135
knowing the source of Candida implicated in infection (recipient, donor, or hospital
acquired) to inform pre-transplant interventions and future treatment will improve
outcomes for SBT patients.
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CHAPTER 4
CONCLUSIONS AND FUTURE DIRECTIONS
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4.1 OUTLOOK ON THE ROLE OF THE GUT MYCOBIOME
Fungi undoubtedly reside in the human gastrointestinal tract and form a small but
persistent part of the gastrointestinal microbiota. So why is it important to understand
their contribution to the gut microbiota as a whole and the human host? Gut mycologists
have only begun to answer this question and have conducted preliminary studies on many
aspects of fungal existence in the gut. Like the bacterial microbiota, there is now
increasing evidence that fungi play a role in the human gut ecology and health. Efforts
need to continue focusing on the function of fungi in the human gastrointestinal tract, as a
myriad of questions remain and the field lags immensely behind bacterial gut microbiota
research. It is gratifying that studies are beginning to question the interactions of fungi
with diet, immune responses, other microbial communities, and diseased states. As the
field advances, studies will unveil the importance of the mycobiome and specific fungal
members as a factor of human health.

4.2 CONCLUSIONS
In Chapter 2, our goal was to help advance and stimulate the relatively new field
of gut mycobiome research. To date, most research has focused on characterizing the
bacterial members of the gastrointestinal tract and the human mycobiome is years behind
the state of the art represented by bacterial microbiome studies. The human gut
mycobiome is diverse and relatively unstable, and the search for a “core mycobiome”
(with the exception of a very few species of human-associated yeasts) may prove futile
due to high level of exposure to environment or food-associated fungi. To date, nextgeneration sequencing platforms show the greatest diversity in gut fungi; however, as so
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many fungi are allochthonous, this high diversity may be misleading and targeted
approaches to identify specific organisms from a limited pool of species of interest may
prove more meaningful. As gut mycologists continue to expand gut mycobiome studies
using larger sample sizes, geographic distribution sampling, dietary influences, and
diseased states we will begin to understand their beneficial and/or detrimental roles in
human health.
In Chapter 3, we surveyed the full gut fungal microbiota of small bowel transplant
patients to determine the source of Candida implicated in candidemia. Using genotyping
methods, we were able to determine endogenous and exogenous sources of Candida
causing candidemia. Although this study has only a limited number of isolates, we were
able to hypothesize that C. albicans and C. glabrata infections were caused by
endogenous sources of Candida and infection with C. parapsilosis was caused from an
exogenous source. The proposed work highlights the wide spread nature of Candida
causing endogenous and exogenous candidemia infections in hospital settings.

4.3 FUTURE DIRECTIONS
Chapter 2 provides a framework for future studies interested in characterizing the
fungi of the gastrointestinal tract. Future studies will need to use larger sample sizes in
order to understand variation of fungal communities between individuals. In addition,
serial samples from individuals need to be collected over time to gain a better
understanding of the stability of gut fungi over time. Culture-dependent and -independent
methods need to be performed in conjunction with one another due to the methodology
biases. Encompassing samples from multiple individuals with different lifestyles, dietary
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habits, and geographic locations will allow researchers to better understand gut mycology
around the world.
Chapter 3 provides baseline data on the gut ecology of Candida yeasts after small
bowel transplantation. In this study it was possible to determine if the gastrointestinal
tract was a potential source of infection. However, due to the limited samples available,
we were unable to determine if the Candida causing infection was from donor or
recipient origin. Donor organs could serve as a source of infection. Collecting,
identifying, and strain-typing Candida yeasts from the donor small bowel at the time of
transplant and the recipient small bowel prior to transplant would allow us to differentiate
between a donor or recipient endogenous source of candidemia.
Collecting donor-recipient ileostomy sample pairs, tracking Candida strain
presence or absence over time for each donor-recipient pair would provide data on which
strains seem to have competitive advantages, and information on the Candida strains
likely to cause candidemia. It would be possible to determine whether strains of Candida
were present in the patient’s microbiota at the time of transplant or were donor-derived.
Also, use of sequencing and strain-typing would: 1) show whether single or multiple
Candida species/strains are present at a given time point, 2) track Candida populations
and prevalence over time and observe whether donor and recipient strains coexist or if
one predominates.
Small bowel transplantation presents a unique opportunity to directly study the
merging of two distinct microbial populations in humans. The use of next generation
sequencing to conduct a comprehensive survey of the gastrointestinal microbiota
(bacteria and fungi) would allow us to evaluate the interactions of two gut microbial
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populations after merging donor and recipient gut microbiomes via transplant. Collecting
samples from both the donor and recipient at the time of transplant would be necessary to
study this. Observing gut microbiota populations over time would allow us to view
ecological processes, such as competition or synergy. Studying the merging of two
microbial communities will allow us to study if donor microbes establish themselves or if
the recipient microbiota is resilient to disturbance. Also, are particular microbes
consistently dominant, regardless of source? And does the abundance of particular
bacterial taxa correlate with Candida abundance or infection?

